

Australian Government Department of Health

Life Saving Drugs Program medicines: Fabry disease

Final Review Protocol

 HealthConsult Pty Ltd

ACN 118 337 821

Sydney Office: 3/86 Liverpool Street, Sydney, New South Wales, 2000 Phone (02) 9261 3707

Melbourne Office: 429/838 Collins Street, Docklands, Victoria, 3008 Phone (03) 9081 1640

18th March 2019

Table of Contents

Section Page

[1 Introduction 2](#_Toc1134198)

[2 ToR 1: Prevalence 4](#_Toc1134199)

[3 ToR 2: Management of Fabry disease in comparison to LSDP guidelines 9](#_Toc1134200)

[4 ToR 3: Clinical and comparative effectiveness and safety of medicines 12](#_Toc1134201)

[5 ToR 4: Relevant patient-based outcomes 18](#_Toc1134202)

[6 ToR 5: Value for money of LSDP Fabry disease medicines 21](#_Toc1134203)

[7 ToR 6: Utilisation of LSDP Fabry disease medicines 26](#_Toc1134204)

[8 ToR 7: Developing technologies that may impact future access 31](#_Toc1134205)

[9 References 35](#_Toc1134206)

[Appendix A : Description of data sources 37](#_Toc1134207)

[Appendix B : Systematic literature review methodology 42](#_Toc1134208)

[Appendix C : Fabry disease in Australia 60](#_Toc1134209)

[Appendix D : Potential Search Terms 64](#_Toc1134210)

[Appendix E : Horizon scan data sources and emerging technology assessment 68](#_Toc1134211)

# Introduction

On the 15th October 2018, the Australian Government Department of Health (the ‘Department’) engaged HealthConsult to undertake: *‘a review of the medicines included on the Life Saving Drugs Program (LSDP)’.*

## Background of the review

The LSDP, administered by the Commonwealth Department of Health, was established in the mid-1990s to provide people with rare and life-threatening diseases access to expensive medicines that were not considered to be cost effective for Pharmaceutical Benefits Scheme (PBS) listing. The LSDP currently fully subsidises 14 life-saving high cost medicines to approximately 400 patients for the treatment of nine rare diseases. In January 2018, following a review of the LSDP, the Australian Government committed to a number of program improvements, including a review of the medicines currently funded under the LSDP and the establishment of an Expert Panel (EP) to provide advice to the Commonwealth Chief Medical Officer (CMO).

## Purpose of the review

The purpose of each of the LSDP reviews (i.e. nine disease-based reviews undertaken in three tranches) is to develop a better understanding of the real-world use of a medicine by comparing the current use performance of the medicine against the recommendations and expectations at the time of listing. The review will assess the clinical benefits achieved through the use of LSDP medicines, ensure the ongoing viability of the program; and ensure testing and access requirements for the medicine remain appropriate.

This Review Protocol for Fabry disease medicines was prepared by HealthConsult. Its development was informed by consultations (with the EP, Fabry disease Clinical Advisory Group (CAG) and LSDP sponsors) as well as a stakeholder forum (including representatives from Fabry Australia, Pharmaceutical Sponsors, EP and CAG members), and a documentation review (e.g. prior reviews of LSDPs, registry publications etc). This final Review Protocol describes the methodology that will be used by HealthConsult to address each Term of Reference (ToR) for the Review of Fabry disease medicines.

## Terms of Reference

The draft ToR for the review of LSDP medicines for Fabry disease were open to public consultation from 14th September 2018 to 5th October 2018. The LSDP Expert Panel considered the draft ToR, together with comments from stakeholders at its 17th October 2018 meeting. The ToR were endorsed by the CMO on 10th December 2018. The seven endorsed ToRs for the Review of LSDP medicines for Fabry disease are:

* **ToR 1:** Review the prevalence of Fabry disease within Australia.
* **ToR 2:** Review evidence for the management of Fabry disease and compare to the LSDP treatment guidelines, patient eligibility and testing requirements for the use of these medicines on the program (including the validity of the tests).
* **ToR 3:** Review clinical effectiveness and safety of medicines and evaluate the evidence of comparative effectiveness of LSDP Fabry disease medicines. This will include analysis of LSDP patient data and international literature to provide evidence of life extension.
* **ToR 4:** Review relevant patient-based outcomes that are most important or clinically relevant to patients with Fabry disease.
* **ToR 5:** Conduct an analysis of the value for money of LSDP Fabry disease medicines under the current funding arrangements.
* **ToR 6:** Review the utilisation of LSDP Fabry disease medicines, including the way they are stored and dispensed, and evidence of patient compliance to treatment.
* **ToR 7:** Investigate developing technologies that may impact future funded access.

It is important to note that the order of the endorsed ToRs, nor the order of research questions or data sources included in the Review Protocol reflect their level of importance or the order in which the Review will occur.

# ToR 1: Prevalence

This Chapter outlines the methodology that will be used to address ToR 1 *“Review of the prevalence of Fabry disease within Australia”.*

The purpose of ToR 1 is to understand the prevalence of Fabry disease within Australia and estimate the future impact of the eligible cohort on the LSDP.

* 1. **Overview of data sources to inform ToR 1**

To address ToR 1, an analysis of the disease prevalence of Fabry disease in Australia will need to be undertaken, where *prevalence* refers to the “number or proportion (of cases, instances, etc.) present in a population at a given time”.1 Table 2.1 presents the research questions to address ToR 1 and the data sources which will be used to answer each of the research questions. Details on the individual data sources are provided in Appendix A.

**Table 2.1: Research questions to address ToR 1**

| **ToR 1 research questions** | **Data sources** |
| --- | --- |
| **Systematic literature review** | **LSDP patient-level data** | **Diagnostic laboratory data** | **Fabry Registry data** | **Stakeholder consultations** |
|  |  |  |  |  |  |
| 1. What is the prevalence of Fabry disease in Australia?
 | + | + | + | + | + |
| 1. What proportion of patients with Fabry disease are eligible to access treatment under the LSDP?
 | - | – | + | + | + |
| 1. What proportion of all eligible Fabry disease patients are accessing the LSDP?
 | - | + | – | + | + |
| 1. Has the prevalence of Fabry disease in Australia changed since government subsidies on drugs for treating Fabry disease became available?
 | + | + | + | + | + |
| **If outcomes of ToR2 indicate a change in eligibility criteria**  |
| 1. What proportion of Fabry disease patients would be eligible for the LSDP if eligibility criteria is modified?
 | - | – | + | + | + |

The following sections explain how each of the identified data sources will be used to inform the analysis undertaken for each of the research questions.

* 1. **Systematic literature review**

A systematic literature review will be undertaken that focuses on identifying published data in peer-reviewed articles on the prevalence of Fabry disease. Published relevant literature will be searched to provide a current look at prevalence numbers. The search will include articles published since 2009. Table 2.2 summarises the literature search criteria that will be used to address ToR 1. Further detail on the systematic review methodology is provided in Appendix B.

**Table 2.2: Literature search criteria for ToR 1**

| **Limit** | **Eligibility criteria** |
| --- | --- |
| Search terms | Synonyms for Fabry disease and an appropriate filter to identify reports relating to the incidence and prevalence of Fabry disease will guide the search. Details of the terms to be used are provided in Appendix D. |
| Databases | * EMBASE
* Medline
* Cochrane Library
 |
| Other means to identify relevant information | * Websites of regulatory agencies: TGA, PBS, FDA, MHRA, EMA
* Public health statistics: ABS, AIHW, Orphanet, HealthData.gov (US), ONS (UK), StatCan (Canada), ANZDATA
* Newborn screening studies
* Manual scan of reference lists
 |
| Publication types | * Full text systematic reviews, literature reviews, clinical trials publications, reports and guidelines reporting on outcome measures for Fabry-specific ERT, and data cubes
 |
| Search period | * Articles published from 2009a
* Conference abstracts published since 2017b
 |
| PICO | * Population: people diagnosed with Fabry disease
* Intervention: not applicable, this is a review of prevalence
* Comparator: not applicable, this is a review of prevalence
* Outcomes: not applicable, this is a review of prevalence
 |
| Exclusions | * Does not relate to patients with Fabry disease
* Does not relate to the prevalence of Fabry disease
 |

Abbreviations: ABS, Australian Bureau of Statistics; AIHW, Australian Institute of Health and Welfare; ANZDATA, Australia and New Zealand Dialysis and Transplant Registry; EMA, European Medicines Agency; ERT, Enzyme replacement therapy; MHRA, Medicines & Healthcare products Regulatory Agency; ONS, Office for National Statistics; PBS, Pharmaceutical Benefits Scheme; TGA, Therapeutic Goods Administration; ToR, Terms of reference.

**a** Prevalence was not previously reviewed in 2015 therefore a 10-year retrospective date limit will be applied

**b** Conference abstracts/posters subject to a two-year restriction to allow for manuscript publication of current evidence

* 1. **LSDP patient-level Data**

The LSDP patient-level data includes information on patients currently receiving subsidised medicines for the treatment of Fabry disease, however, not all eligible patients may be receiving treatment with agents available through the LSDP (refer to 2.8 on Limitations). The patient-level program data is updated through an annual re-application process. The number of patients approved for LSDP medicines will be used to inform the prevalence of Australians diagnosed with Fabry disease from when the program commenced data collection on patient applications/re-applications.

It is noted that Australian Fabry disease patients who fail to meet the eligibility criteria set out by LSDP Guidelines are not registered nor monitored in the LSDP patient-level data. Hence this data source is likely to provide an underestimate of the actual prevalence. However, the LSDP patient-level data will only be one data source, albeit an important data source, used as a basis to inform the estimation of prevalence of Fabry disease in Australia. The LSDP patient-level data should provide a solid basis for informing the prevalence of Fabry disease patients who are receiving subsidised therapy within Australia.

* 1. **Diagnostic laboratory data**

Although the diagnosis of Fabry disease can be delivered by clinicians working across several Australian health care services, there are a limited number of laboratories in Australia that perform the testing to diagnose Fabry disease. As such, attempts will be made to access data from these laboratories to estimate the incidence of new cases of Fabry disease. Annual incidence of new cases, since 2009 (if the data is available) can then be used in conjunction with the expected mortality rate of Gaucher disease to calculate and project the prevalence of Gaucher disease prevalence figures and expected mortality rate to calculate and project disease prevalence.

## Fabry disease Registry data

HealthConsult will seek to access Fabry disease registry data. There are two key sponsor-supported registry databases of relevance including:

* **The Fabry Registry**: part of the Rare Disease Registries sponsored by Sanofi Genzyme and accessed through the web-based portal RegistryNXT.2 It is an international, observational, and voluntary program designed to collect patient clinical data related to the onset, progression, and treatment course of Fabry disease. The Fabry disease registry is registered as a clinical trial involving 203 international study sites, of which, five locations are situated in Australia for the recruitment of local patients diagnosed with Fabry disease.3
* **The Fabry Outcomes Survey (FOS)**: an international longitudinal observational registry sponsored by Shire for patients diagnosed with Fabry disease and are receiving agalsidase alfa therapy. The FOS provides long-term data on the safety and efficacy of agalsidase alfa therapy. In 2016, 131 Australian patients were registered in the FOS, making up 4% of all international patient recorded (n = 3,112).4

The number of Australian patients in the registries will be factored into determining the present Fabry disease prevalence. Changes in the annual number of registered Australian patients since 2009 will also be analysed.

* 1. **Stakeholder consultations**

Expert opinion will be used to supplement information retrieved through other ToR 1 data sources described above. Expert opinion, will be sought from clinicians and peak consumer organisations, to inform factors affecting disease prevalence in Australia; to determine the number of Fabry disease patients being treated within and outside the LSDP; the reasons why individuals are not accessing LSDP drugs; if any Fabry disease patients are eligible for the program but elect alternative treatment; and number of patients enrolled in clinical trials.

Expert opinion will be used to supplement other ToR 1 data sources as a means of reducing uncertainty, particularly with incomplete or outdated sources of information.5 Guidance provided in Appendix 1 of the PBAC Guidelines (v5.0) will inform the approach that will be used to elicit and present expert opinion.

* 1. **Synthesis of findings**

Attempts will be made to identify specific measures of prevalence relating to:

* total prevalence versus prevalence of patients eligible for treatment with enzyme replacement therapy (ERT) under the LSDP
* proportion of eligible patients who are treated under the LSDP
* prevalence of asymptomatic individuals with a confirmed diagnosis, for instance, individuals who are positive for genetic biomarkers of Fabry disease and display normal enzyme levels and/or mild symptoms
* prevalence of adults (aged 18 and over) versus paediatric patients, and
* prevalence of male versus female patients.

These indicators of disease prevalence will be comparatively analysed across different data sources to inform ToR 1 including: systematic literature review, the LSDP patient-level data, LSDP dispensing data, diagnostic laboratory datasets, and the various Fabry disease registries.

The systematic review will provide an evidence base of secondary sources indicating the prevalence of Fabry disease patients in Australia. This evidence base will be used to address research questions 1 and 3 of ToR 1. HealthConsult may either directly extract or adapt any in-scope prevalence and/or population statistics from article inclusions. Any statistical insight into incidence rates and/or mortality rates are likely to influence total count of Fabry disease cases over time and may therefore need to be factored into calculations to determine total disease prevalence.

Research question 3 will be addressed by taking the number of patients observed in the LSDP patient-level dataset as a proportion of the eligible population, as determined in ToR 1 research question 2. The eligible population will be determined via:

* analysis of Australian diagnostic laboratory datasets that include information on patient characteristics related to the LSDP eligibility criteria; and/or
* estimation by subtracting the number of ineligible patients (such as those enrolled in clinical trials) from total disease prevalence estimated in research question 1.

Variations in the annual statistics of Fabry disease cases, pre and post introduction of the LSDP subsidised medicines, will be used to inform research question 4. Additionally, discussion pieces from authors of systematic reviews may also be incorporated into the analysis to provide context around related data, for instance, discussion on driving factors behind change in prevalence over time. The data obtained may also assist to better understand the number of new patients expected to be diagnosed annually.

The true prevalence of Fabry disease may be difficult to ascertain however estimates can be obtained through various data sources. Additional data sources provide prevalence estimates by proxy however under and over reporting of prevalence should be considered when analysing of results.

The discussion will also include the applicability of the results of the trials to the population for whom ERT is available on the LSDP and, also, the population for who ERT should be available, if findings from ToR 2 indicate that a change to current eligibility criteria might be warranted.

* 1. **Limitations**

It is noted that some Australian Fabry disease patients may not be identified in the LSDP patient-level data. Some patients may be exclusively registered on international registries if, for instance, they have sought novel treatment modalities. While publications based on clinical trials data typically identify countries of patient recruitment sites and/or country of patient cohorts, the data in these articles are often presented at aggregate level where Australian data is mixed in with international cohorts. Attempts will be made to retrieve Australian data from commercial registries which are used for clinical trials. Without this trial data, total Australian disease prevalence calculations will likely represent an underestimate. Attempts will be made to access data from Australian diagnostic pathology laboratories to obtain evidence to supplement the LSDP patient-level data.

The accuracy of disease prevalence calculations will rely heavily on information about Australian patient numbers in clinical trials, and commercial patient registries.

A limitation faced in ToR 1 will be the availability and completeness of identified datasets. Patient privacy guidelines will prevent the obtainment of patient-level data which can be ability to cross-referenced and to identify individuals who may be included in multiple datasets to be used in ToR 1. This will impact estimation of the eligible population. Determination of incidence of new patients diagnosed in Australian will likely depend on access to pathology laboratory datasets. The limitation with these datasets includes potential double counting and/or duplication captured by multiple diagnostic laboratories. Within National Reference Laboratories (NRL) all confirmed diagnosis of enzyme activity may be remeasured in some patients and screening for Fabry disease conducted in remote laboratories is recaptured in the NRL. Also gaps in the data may be due to family members surrounding an index case that refuse screening, asymptomatic and late onset patients who have yet to be screened and those that qualify for LSDP medicines and do not use it.

# ToR 2: Management of Fabry disease in comparison to LSDP guidelines

This Chapter outlines the methodology that will be used to address ToR 2 *“Review evidence for the management of Fabry disease and compare to the LSDP treatment guidelines, patient eligibility and testing requirements for the use of these medicines on the program (including the validity of the tests).”* An overview of the diagnosis and management of Fabry disease (including a clinical algorithm) is in Appendix C.

The purpose of ToR 2 is to:

* understand how the LSDP patient eligibility criteria (including initial and ongoing testing protocols and their validity) compares against best practice management of Fabry disease, both domestically and internationally, and
* determine which approach is the most appropriate based on available evidence if there is a variation between clinical practice and LSDP patient eligibility.
	1. **Overview of data sources to inform ToR 2**

To address ToR 2, a comparative analysis of the evidence on the diagnosis and management of Fabry disease both internationally and locally, will need to be undertaken, and compared to how this evidence aligns with the current LSDP guidelines. Table 3.1 presents the research questions to address ToR 2 and the data sources which will be used to answer each of the research questions. Fundamentally, the research questions seek to understand how the patient eligibility criteria (including testing protocols and the validity of those testing protocols) required for access to ERT under the LSDP compare with international clinical guidelines (e.g. are the LSDP criteria more extensive or concise than recommended in treatment guidelines internationally). Details on the individual data sources are provided in Appendix A.

**Table 3.1: Research questions to address ToR 2**

| **ToR 2 research questions** | **Data sources** |
| --- | --- |
| **Systematic literature review** | **LSDP patient-level data** | **Stakeholder consultation** |
|  |  |  |  |
| 1. What is the current best practice model for the diagnosis and management of Fabry disease (i.e. adult and paediatric)? What is the quality of evidence underpinning this approach?
 | + | - | + |
| 1. What are the eligibility criteria for initial and ongoing access to LSDP medicines? What is the quality of evidence underpinning these requirements?
 | + | + | + |
| 1. Are there any inconsistencies between clinical best practice and the LSDP eligibility criteria? If yes, which is more appropriate based on evidence?
 | + | + | + |

The following sections explain how each of the identified data sources will be used to inform the analysis undertaken for each of the research questions.

* 1. **Systematic literature review**

The systematic literature review will focus on identifying the clinical indications for, and management of Fabry disease with LSDP medicines. Table 3.2 summarises the literature search criteria that will be used to address ToR 2. Ideally, literature will be available to provide insight into international treatment algorithms and/or similar international programs, national/international guidance documents, testing regimes and treatment modalities for different Fabry populations (such as adult compared to paediatric).

Further detail on the systematic review methodology is provided in Appendix B. The relevant PubMed search string can be found in Appendix D (refer to Section D.2).

**Table 3.2: Literature search criteria for ToR 2**

| **Limit** | **Eligibility criteria** |
| --- | --- |
| Search terms | Synonyms for Fabry disease and an appropriate filter to identify clinical guidelines will guide the search. Details of the terms are provided in Section D.2 of Appendix D. |
| Databases | Peer reviewed articles* EMBASE
* Medline
* Cochrane Library

Clinical guidelines* Guideline Central ([www.guidelinecentral.com](file:///G%3A%5CMy%20Drive%5Cunshared%20-%20HTA%20-%20LSD%20Program%5CProtocol%5Cwww.guidelinecentral.com))
* Australian Clinical Practice Guidelines Portal ([www.clinicalguidelines.gov.au](http://www.clinicalguidelines.gov.au))
* G-I-N ([www.g-i-n.net](http://www.g-i-n.net))
* NORD ([ww.rarediseases.org](https://rarediseases.org))
* AHRQ ([www.ahrq.gov](http://www.ahrq.gov))
* SIGN ([www.sign.ac.uk](http://www.sign.ac.uk))
* NICE ([www.nice.org.uk](http://www.nice.org.uk))
 |
| Other means to identify relevant information | * PBAC PSDs for Fabry disease medicines
* Product information documents for Fabry disease medicines on the ARTG
* Other relevant websites (e.g. Rare Voices Australia, Fabry Australia)
 |
| Publication types | * Australian and international evidence-based clinical practice guidelines on the pharmacological management of Fabry disease
 |
| Search period | * Articles published from 2012a
* Conference abstracts published since 2017b
 |
| Exclusions | * Not an evidence-based clinical practice guideline (e.g. position statements with no references)
* Guidance does not relate to Fabry disease
 |

Abbreviations: AHRQ, Agency for Healthcare Research and Quality; ARTG, Australian Register of Therapeutic Goods; G-I-N, Guideline International Network; NICE, National Institute for Health and Care Excellence; NORD, National Organization for Rare Disorders; PBAC, Pharmaceutical Benefits Advisory Committee; PSD, Public Summary Document; SIGN, Scottish Intercollegiate Guidelines Network; ToR, Term of Reference

**a** Administration and guidelines were reviewed as part of LSDP ToR 2015 review.

**b** Conference abstracts/posters subject to a two-year restriction to allow for manuscript publication of current evidence

* 1. **LSDP patient-level data**

The LSDP patient-level data will provide real-world evidence on which medical tests are performed to determine (a) whether patients are eligible for initiation of treatment and (b) whether patients initiated on treatment are eligible for continued access to subsidised Fabry disease treatment in Australia. An analysis of the type and frequency of tests administered for LSDP application/re-application will be undertaken. This data will be required to describe what tests are currently being undertaken on patients on the LSDP and the adherence to the annual testing requirements.

* 1. **Stakeholder consultation**

The use of expert opinion to address the research questions in the review will follow the methods described in Appendix A of the PBAC guidelines.6 This includes detailing the criteria for selecting experts, number of stakeholders/experts approached, number who provided information, methods used to collect responses, questions asked and others.

Questions asked of stakeholders will be aimed at obtaining information which could not be obtained through any other source.

Stakeholders, including clinicians, clinical advisory group (CAG) clinicians and Fabry Australia, will be approached to provide comments and insight into:

* the current access criteria
* the role of the required tests in making clinical decisions and in-patient monitoring
* the ongoing access criteria for patients (paediatric and adult cohort)
* the impact of LSDP requirements on a clinician’s service.

Any conflicting opinions arising through the consultation process will be also be managed as is consistent with guidance provided by the PBAC guidelines.6 As multiple sources of opinion would be available, results will be compared and their concordance (or lack thereof) will be assessed. Consequently, once assessed, a justification for the choice of data to be used in the review will be provided. As part of the assessment (where possible) stakeholders’ opinions will be compared to the literature.

* 1. **Synthesis of findings**

The systematic review will seek to identify key recommendations in clinical guidelines (local and international) for assessing a Fabry disease patient’s suitability for ERT. The review will outline the eligibility criteria that patients need to meet to obtain access to ERTs that are funded under the LSDP.  Eligibility criteria in terms of baseline, initial response criteria, continuation criteria and the clinical utility of these tests over time will be examined. This will include subpopulation analysis where possible (e.g. paediatric and adult). The quality of evidence supporting the clinical recommendations and eligibility criteria will also be assessed. Consequently, these two parameters will be compared, and the more appropriate of the two will be determined based on the quality of the available evidence. Using qualitative data gathered through stakeholder consultations together, with secondary data sources, will provide the evidence base to answer research questions 1, 2 and 3 of ToR 2.

* 1. **Limitations**

There is the possibility that there are (a) no formal clinical guidelines for the treatment of Fabry disease, and (b) differences in clinical practice by treating physicians. In addition, clinical algorithms and patient management pathways from international sources may differ to the Australian Fabry disease pathways due to different patient demographics or national health policies. For example, treatments used in other countries may not be available in Australia. These differences will be assessed and discussed. It is also possible that not all patient tests recommended by the LSDP guidelines are performed on each patient and/or this data is submitted to the Department as part of the application processes. Consequently, this could impact on the assessment as to whether the current recommendations and eligibility for accessing LSDP medications are being met.

# ToR 3: Clinical and comparative effectiveness and safety of medicines

This Chapter outlines the methodology that will be used to address ToR 3 *“Review clinical effectiveness and safety of medicines and evaluate the evidence of comparative effectiveness of LSDP Fabry disease medicines. This will include analysis of LSDP patient data and international literature to provide evidence of life extension.”*

The purpose of ToR 3 is to review the available evidence investigating the effectiveness and safety of current LSDP Fabry medicines (agalsidase alfa and agalsidase beta) and compare this to the natural history of the disease in the absence of such treatments and to the initial expectations at the time of listing on the LSDP. The treatments will also be compared to each other.

* 1. **Overview of data sources to inform ToR 3**

To address ToR 3, current LSDP subsidised medicines, agalsidase alfa and agalsidase beta will be compared to standard treatment of care in the absence of LSDP medicines and against each other. Comparisons based on alternate dosing schedules will also be investigated as will any evidence on the stabilisation of disease progression and/or extension of survival due to Fabry disease medicines. Table 4.1 presents the research questions to address ToR 3 and the data sources which will be used to answer each of the research questions. Details on the individual data sources are provided in Appendix A.

**Table 4.1: Research questions to address ToR 3**

|  |  |
| --- | --- |
| **ToR 3 research questions** | **Data sources** |
| **Systematic literature review** | **LSDP patient-level data** | **LSDP dispensing data** |
| **Clinical effectiveness and safety**  |
| 1. How does the effectiveness and safety of agalsidase alfa compare to when it was listed on the LSDP?a, b
 | + | + | + |
| 1. How does the effectiveness and safety of agalsidase beta compare to when it was listed on the LSDP? a, b
 | + | + | + |
| 1. What is the effectiveness and safety of agalsidase alfa compared to agalsidase beta? How does this compare to the original estimates at the time of LSDP listing? a, b
 | + | + | + |
| **Life extension** |  |  |  |  |
| 1. Is there evidence that the Fabry disease medicines have stabilised disease progression and/or extended survival?a, b
 | + | + | + |
| 1. Are the age-adjusted rates of mortality different between Fabry disease medicines (or to natural disease history)? a, b
 | + | + | + |
| **If outcomes of ToR2 indicate a change in eligibility criteria**  |
| 1. What is the effectiveness and safety of agalsidase alfa in alternate populations?c
 | + | + | + |
| 1. What is the effectiveness and safety of agalsidase beta in alternate populations?c
 | + | + | + |
| 1. What is the effectiveness and safety of agalsidase alfa compared to agalsidase beta in alternate populations?c
 | + | + | + |

Abbreviations: HTA, Health Technology Assessment; LSDP, Life Saving Drugs Program; ToR, Term of Reference

**a** Search will be restricted to capture original pivotal trials that informed the medicines inclusion on the LSDP are required to inform clinical effectiveness and safety research questions.

**b** Search will be restricted from 2012 to identify any new evidence since the last LSDP 2015 published report with a 2-year retrospective evidence retrieval and evaluation

**c** Unrestricted search date as evidence has not previously been seen by LSDP EP

The primary population of interest, patients with Fabry disease, is defined by the current LSDP eligibility guidelines, which require confirmation of the diagnosis of Fabry disease by demonstration of specific deficiency of alpha-galactosidase enzyme activity in blood or white cells or by the presence of genetic mutations (i.e. known to result in deficiency of alpha-galactosidase enzyme activity) and that the patient has Fabry-related renal disease and/or cardiac disease and/or ischaemic vascular disease and/or uncontrolled pain.7 However, if outcomes of ToR 2 indicate that a change in eligibility criteria may be warranted, outcomes in alternate populations will also be presented. Outcomes for all the primary endpoints and the key secondary and exploratory endpoints assessed in the studies will be presented. At a minimum, key efficacy and safety outcomes presented in the original submissions seeking reimbursement will again be presented. However additional outcomes may be presented if the findings from ToR 4 indicate that other outcomes are important from a clinical or patient perspective. Table 4.2 presents a PICO.

**Table 4.2: PICO supporting ToR 3**

| **Criteria** | **Description** |
| --- | --- |
| Study design | The primary objective of the literature search is to locate all randomised trials comparing agalsidase alfa and agalsidase beta to placebo and agalsidase alfa and agalsidase beta to each other to identify head to head studiesa |
| Population | Australian Fabry disease patients who are eligible to receive LSDP funded medicines  |
| Intervention | Enzyme replacement therapy (ERT)* agalsidase alfa (Replagal)
* agalsidase beta (Fabrazyme)
 |
| Comparator | * supportive care (or placebo in initial RCT)
* agalsidase alfa (Replagal) agalsidase beta (Fabrazyme)
 |
| Outcomes | * Results for primary endpoints assessed by the retrieved studies will be presented
* Results for key secondary and exploratory endpoints assessed by the studies will be presented
* At a minimum (and to the extent that they are available), results for the following outcomes (which were judged as being important at the time the ERTs for Fabry disease were reimbursed under the LSDP) will be reported:
	+ incidence of and time to occurrence of key clinical events including:
		- key renal events (e.g., reduction in GFR, proportion of patients with and time to end-stage renal disease, etc)
		- key cardiac events (e.g., change in left ventricular mass, change in left ventricular ejection fraction, proportion of patients experiencing and time to experiencing of cardiac events such as infarction, unstable arrythmia, implant of cardiac device, etc), and
		- key cerebrovascular events (e.g., proportion of patients experiencing and time to stroke, transient ischaemic attacks, etc)
	+ pain-related measures (including incidence and severity of pain and extent of use of pain medication)
	+ quality of life
	+ overall survival
	+ safety and adverse events related to agalsidase alfa and agalsidase beta treatment
* In addition, outcomes for other endpoints that may be of interest given the findings from ToR 2 will be presented (to the extent that they are available)
 |
| Other SLR considerations  | * No study size limits will apply
* Subgroup analysis: by dose (e.g. doses consistent with TGA listing, as well as experimental dosing regimens) by age (stratified by paediatric and adult)
 |

Abbreviations: ERT, enzyme replacement therapy; GFR, Glomerular filtration rate; LSDP, Life Saving Drugs Program; RCT, randomized controlled trial; SLR; systematic literature review; TGA, Therapeutic Goods Administration

**a** If direct head to head trials are not identified a search will be conducted for randomised trials of either the proposed medicine or the main comparator to generate an indirect treatment comparison. If no trials are suitable for an indirect treatment comparison the search will be broadened to identify nonrandomised trials.

Table 4.3 summarises the literature search criteria that will be used to address ToR 3. Further detail on the systematic review methodology, potential search terms for PubMed and other data sources are provided in Appendix D.

Table 4.3: Literature search criteria for ToR 3

|  |  |
| --- | --- |
| **Limit** | **Eligibility criteria** |
| Search termsa | * Synonyms for Fabry disease and an appropriate filter to identify articles on clinical effectiveness and safety will guide the search. Details of the terms are provided in Section D.3 of Appendix D.
 |
| Databases of peer-review literature | * EMBASE (Embase.com)c
* Medline (via PubMed)d
* Cochrane Library Databases (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials)e
 |
| Other means to identify relevant information | * ClinicalTrials.govf
* International Clinical Trials Registry Platformg
* Australian Clinical Trials Registryh
* Internal registries (Original PBAC funding application pivotal trials that informed the medicines inclusion on the LSDP)
* Other (Hand-searching of primary articles to identify additional studies; Database of Adverse Events Notifications Data from ARTG; PBAC PSD for agalsidase alfa or agalsidase beta; Product information documents for Fabry disease medicines on the ARTG; AIHW National Death Index data and Cause of Death data; Shire and Genzyme websites, Fabry disease registry and FOS published registry data reports)
 |
| Publication types | * Studies in humans
* Studies published in English and articles not published in English
* Exclude: editorials, letters, non-clinical studies
 |
| Search period | * Evidence from the initial LSDP listing trials will be includedi
* Articles published from 2012j
* Conference abstracts published since 2017k
 |
| Study exclusion criteriab | * Duplicate data
* Wrong study type: Not a randomised controlled trial
* Wrong population: Does not include patients with Fabry disease
* Wrong intervention: Incorrect intervention (not agalsidase alfa (Replagal) or agalsidase beta (Fabrazyme))
* Wrong comparator: Not compared to the relevant comparator (placebo (or standard therapy in absence of placebo); agalsidase alfa (Replagal) or agalsidase beta (Fabrazyme) for direct head to head studies))
 |

Abbreviations AIHW, Australian Institute of Health and Welfare; ARTG, Australian Register of Therapeutic Goods; FOS, Fabry Outcome Survey; LSDP, Life Saving Drugs Program; MeSH, medical subject headings; PBAC, Pharmaceutical Benefits Advisory Committee; PSD, Public Summary Document; RCTs, Randomised Controlled Trials

Notes: **a** Potential search terms are located in Appendix D

**b** Selection process will be adapted when relying on an indirect comparison of randomised trials or nonrandomised evidence

**c** https://www.embase.com

**d** https://www.ncbi.nlm.nih.gov/pubmed

**e** https://www.cochranelibrary.com

**f** https://clinicaltrials.gov

**g** https://www.who.int/ictrp

**h** http://www.anzctr.org.au/

**i** Search will be restricted to capture original pivotal trials that informed the medicines inclusion on the LSDP are required to inform clinical effectiveness and safety research questions

**j** Search will be restricted from 2012 to identify any new evidence since the last LSDP 2015 published report with a 3-year retrospective evidence retrieval and evaluation

**k** Conference abstracts/posters subject to a two-year restriction to allow for manuscript publication of current evidence

* 1. **Systematic literature review**

A systematic literature review will be conducted to address ToR 3. From this literature, the effectiveness and safety of agalsidase alfa and agalsidase beta in a clinical trial setting will be determined. The primary objective of the systematic literature review is to identify all RCTs in the proposed population to allow a comparison of the effectiveness and safety of the medicines in the trial setting with effectiveness and safety of the medicines as observed in practice in LSDP patients.

A comparison of outcomes achieved with agalsidase alfa and agalsidase beta will also be conducted. If direct RCTs comparing agalsidase alfa to agalsidase beta are not identified, a search will be conducted to identify RCT trials of either agalsidase alfa or agalsidase beta against placebo. These trials can be used to conduct an indirect treatment comparison. If the direct RCTs or other RCTs retrieved are not suitable for an indirect comparison, the original search will be broadened to identify all non-randomised studies of patients with Fabry disease comparing agalsidase alfa to agalsidase beta.

The systematic literature review will be conducted in accordance with PBAC Guidelines (v 5.0). If necessary (e.g. if data for a key patient relevant endpoint are not captured by RCTs), data from RCTs will be supplemented with data from non-randomised studies (e.g. cohort studies, case-control studies and quasi-experimental studies). Outcomes will be directly related to the quality and/or length of a patient’s life and will constitute the best available clinical evidence to support the effectiveness and safety of the LSDP medicine. The study selection process for each search will be presented in a PRISMA flowchart (see Appendix B, Section B.4). A list of included trials and excluded trials and reasons for exclusion will be provided. If an indirect comparison is required, a network diagram will be provided to show common reference links. Heterogeneity and potential for bias within and across trials will be assessed. Important differences in quality of methods of trials, differences in patient characteristics, differences in circumstances of use of treatment and the potential for such differences to confound results will be discussed. In addition, the appropriateness of the endpoints assessed in the trials and methods of statistical analysis of those endpoints will also be assessed.

Original PBAC funding application pivotal trials that informed the medicines inclusion on the LSDP will be identified in a separate systematic literature review search. In addition to the published evidence, sponsors of the medicines included on the LSDP will be invited to provide unpublished clinical study reports (CSRs) relating to any potentially relevant trials.

* 1. **LSDP patient-level data**

Treating clinicians who wish to apply for their patients to receive LSDP medicines are required to declare that their patient meets the criteria for initial and ongoing eligibility to access subsidised treatment. As part of the LSDP subsided medicine re-application process, clinicians must demonstrate clinical improvement in their patients or stabilisation of the patient’s condition to support ongoing eligibility for the treatment of Fabry disease. Hence this information is captured in the LSDP patient-level data.

To inform research question 1, 2 and 3 (clinical effectiveness and safety in trials versus outcomes observed in patients on the LSDP), an analysis of the LSDP patient-level data will be undertaken to assess the impact of each medicine on outcomes over time (by medicine type). The results of these analyses will be compared against the pivotal trial estimates that informed the LSDP medicine listing. The data will also be analysed to assess the impact, if any, of increasing weight/dose/age/comorbidities on haematological, urinalysis, cardiac, renal, cerebrovascular and pain outcome events. Individual patient trajectories and dose response curves will also be generated and compared across different LSDP Fabry disease medicines. Rates of adverse events will be compared and contrasted across dose, age, date of diagnosis, alternative treatment regimens and again compared to original pivotal trial results. The limitations to this analysis are discussed in Section 4.6.

To inform research questions 4 and 5 (stabilised disease progression and/or life extension), an analysis of LSDP patient-level data will be used to describe the demographic profile (including age, gender) of patients by LSDP medicine prescribed. Together with data on the date of commencement and cessation, HealthConsult will profile the effect of the medicine on stabilised disease progression and/or life extension and mortality in the Australian population accessing LSDP medicines for Fabry disease. This data will be compared to the natural history of the disease, mortality and the stabilised disease progression and/or life extension effects of different Fabry disease medicines identified in the systematic literature review.

* 1. **LSDP dispensing data**

LSDP patient-level data linked to LSDP dispensing data will allow analysis to assess the impact of variations around recommended dose regimens on the clinical effectiveness over time as well as the impact of age on outcomes. These analyses will inform research question 1, 2 and 3. The analysis will include descriptive statistics on date of dispensing, date of infusion, number of days between dispensing and dispensed amount, supplemented by analysis of clinical notes (where appropriate). Together this information will inform whether there are any clinical trends with variations in dose and/or age. Additional analysis will be presented comparing consistencies in dosing against agalsidase alfa and agalsidase beta from the recommended doses in the original pivotal trials and the TGA recommended dose in the product information (PI).

* 1. **Synthesis of findings**

The clinical effectiveness and safety research questions 1, 2 to 3 will be informed by an analysis of the totality of the available published evidence (and any relevant unpublished evidence that may be provided by sponsors). And additional evidence that has been generated since the PBAC’s consideration of the products listed on the LSDP. Questions 1, 2 and 3 will also be informed by LSDP patient data outcomes. All analyses will be supplemented by any evidence identified in the systematic literature review relating to clinical effectiveness and safety generated at the time of PBAC’s consideration of the products listed on the LSDP compared to post 2012 (i.e. post 2015 review).

Research question 3 will require additional analysis to include a comparative analysis of the effectiveness and safety of the medicines listed on the LSDP based on the published evidence (and unpublished evidence provided by sponsors) and based on analysis of patient-level data from the LSDP program. To the extent that it is possible, differences in haematological, urinalysis, cardiac, renal, cerebrovascular and pain endpoints will be assessed. Also, LSDP dispensing data will be used to analyse trends (by descriptive statistics on date of dispensing, infusion, days between dispenses and amount) to confirm consistency in efficacy against original trials and between different treatments, as well as exploring the impact of patient compliance to treatment (note that compliance will be further explored in ToR 6). Finally, we will compare the doses currently being used to the dosing used in the original trials to the recommended dose in the TGA approved product information.

Stabilised disease progression and/or life extension research questions 4 and 5 will be informed by the systematic literature review on the natural history of Fabry disease and stabilised disease progression and/or mortality/survival, analysis of LSDP patient-level data and LSDP medication duration. To gain a comprehensive understanding on the effects of LSDP medicines on patient longevity and age-adjusted survival, we will seek to do an analysis of AIHW National Death Index data and Cause of Death data to LSDP patient-level data.

The information gathered for ToR 3 will be presented in accordance with the guidance provided in Section 2 of the current PBAC guidelines. For example, the information in the publications identified by the systematic literature review will include assessment of internal validity; a presentation of the interventions(s) and comparators assessed by the trials, patient characteristics in the trials, endpoints assessed by the trial and the methods of statistical analysis, efficacy and safety outcomes of the trials. Any relevant subgroup analyses or meta-analysis will also be presented. Finally, treatment effect variation that is related to differences between the trial setting and the Australian setting will be discussed. The discussion will also include the applicability of the results of the trials to the population for whom ERT is available on the LSDP and, also, the population for who ERT should be available, if findings from ToR 2 indicate that a change to current eligibility criteria might be warranted.

* 1. **Limitations**

The quality of LSDP patient-level data could represent a major limitation in the evaluation of effectiveness. Factors that may cause bias in the LSDP patient-level data include:

* loss to follow up (patients that discontinue treatment due to disease progression, mortality or adverse events; overseas relocation; personal choice; participation in a clinical trial)
* missing/inconsistent outcome data
* deviations from recommended dose regimen
* variations in time on treatment
* age of initiation of treatment
* severity of disease.

HealthConsult will conduct a sensitivity analysis to test the robustness of certain assumptions from the patient-level program data and separate results on particular outcomes if the data is available.

Other limitations include:

* A lack of a control group in patients on the LSDP program as data is collected on symptomatic patients who qualify for LSDP funded medicines. There is no asymptomatic or ‘control group’ of patients that have Fabry disease and who do not qualify for LSDP funded medicines. The Fabry registry may provide information on patients not eligible for LSDP medicines. This will be further investigated and utilised if suitable.
* The difficulty in analysing the difference between progression of the natural history of Fabry disease versus the impact of aging.
* Impact of stock shortages and forced switching protocols.

Overall, if the patient level program data has a high level of uncertainty it may not be appropriate to perform inferential statistics and descriptive statistics may be more appropriate.

# ToR 4: Relevant patient-based outcomes

This Chapter outlines the methodology that will be used to address ToR 4 *“Review of relevant patient-based outcomes that are most important or clinically relevant to patients with Fabry disease”.*

The purpose of ToR 4 is to identify the treatment outcomes that are highly valued by patients with Fabry disease and their clinicians.

* 1. **Overview of data sources to inform ToR 4**

To address ToR 4, an analysis of patient-based outcome items for patients receiving medicines funded under the LSDP will need to be undertaken. ‘Patient-based outcomes’ are also known as ‘patient-centred outcomes’ or ‘patient-reported outcomes’ (PRO) and refer to “how health services and interventions have, over time, affected a patient’s quality of life, daily functioning, symptom severity, and other dimensions of health which only patients can know”.8 Table 5.1 presents the research questions to address ToR 4 and the data sources which will be used to answer each of the research questions. Details on the individual data sources are provided in Appendix A.

**Table 5.1: Research questions to address ToR 4**

| **ToR 4 research questions** | **Data sources** |
| --- | --- |
| **Systematic literature review** | **LSDP patient-level data** | **Stakeholder consultation** |
|  |  |  |  |
| 1. What outcomes are most important to paediatric and adult patients who are being treated with LSDP medicines for Fabry disease and their clinicians?
 | + | + | + |
| 1. How can administration of the LSDP be improved (within reason) to help patients with Fabry disease and their clinicians? Does the administration need to be different for paediatric and adult patients?
 | – | – | + |

The following sections explain how each of the identified data sources will be used to inform the analysis undertaken for each of the research questions.

* 1. **Systematic literature review**

The systematic review will focus on identifying Fabry disease PROs related to ERT. Table 5.2 summarises the literature search criteria that will be used to address ToR 4. Further detail on the systematic review methodology is provided in Appendix B.

**Table 5.2: Literature search criteria for ToR 4**

| **Limit** | **Eligibility criteria** |
| --- | --- |
| Search terms | Synonyms for Fabry disease and an appropriate filter to identify reports relating to the incidence and prevalence of Fabry disease will guide the search. Details of the terms to be used are provided in Section D.4 of Appendix D.  |
| Databases of peer-review literature | * EMBASE
* Medline
* Cochrane Library
 |
| Other means to identify evidence | * Clinical trial articles included for analysis in ToR 3
* Clinician input and Clinician international sponsor registry data
* Scan for relevant grey literature, including reports from Fabry disease patient organisations and peak bodies
* Scan of social media, blogs, and self-help websites for PROs and PRO-like patient concerns regarding their treatment experience
* Patient-centred outcomes research online resources such as:
* PCORI ([www.pcori.org](http://www.pcori.org))
* ISPOR ([www.ispor.org](http://www.ispor.org))
* The Hastings Center ([www.thehastingscenter.org](http://www.thehastingscenter.org))
* PROMIS ([www.healthmeasures.net](http://www.healthmeasures.net))
* COMET (www.comet-initiative.org)
 |
| Publication types | * Full text reviews, clinical trials, reports and guidelines reporting on patient-centred outcome measures for the treatment Fabry disease.
* English language and reputable trials not published in English (translated by an external provider)
 |
| Search period | * Articles published from 2012a
* Conference abstracts published since 2017b
 |
| Study exclusion criteria | * Does not relate to patients with Fabry disease.
* Does not relate to patient-centred outcomes.
* A patient questionnaire or outcome measurement tool without reporting on results.
 |

Abbreviations: CAG, Clinical Advisory Group; COMET, Core Outcome Measures in Effectiveness Trials; ISPOR, International Society for Pharmacoeconomics and Outcomes Research; LSDP, Life Saving Drugs Program; PCORI, Patient-Centered Outcomes Research Institute; ToR, Term of Reference.

**a** Search will be restricted from 2012 to identify any new evidence since the last LSDP 2015 published report with a 3-year retrospective evidence retrieval and evaluation

**b** Conference abstracts/posters subject to a two-year restriction to allow for manuscript publication of current evidence

* 1. **LSDP patient-level data**

The LSDP patient-level data contains patient monitoring and outcomes data related to the quality of life whilst on ERT. This data source will provide both the data and the domains or measures of quality of life (from PRO measures or PROM tools) that will be cross-referenced with findings from the ToR 4 systematic review and stakeholder consultations to address research question 1.

* 1. **Stakeholder consultations**

HealthConsult intend to consult with (i) consumers and/or consumer advocacy groups (e.g. Fabry Australia), (ii) clinicians and (iii) sponsors. Input from consumers is crucial in addressing all ToR 4 research questions. Stakeholder engagement to seek expert opinion on patient-relevant outcomes will occur in line with current PBAC Guidelines.5

The stakeholder consultation process will be designed to gather data to address ToR 4 research questions. The gathering of stakeholder input may include focus groups, an online survey, teleconference, webinar(s) and/or one-on-one interviews (by telephone, face-to-face and/or via videoconference). Prior to the stakeholder consultations, all invited individuals will be provided with a stakeholder interview/forum protocol (except those providing input by online survey). The protocol will explain the purpose of the interviews/forums as well as include a list open-ended questions which will be used to facilitate discussions. The online survey will set the context through a brief presentation of information prior to commencement of the survey.

Stakeholder consultations will begin with a presentation of patient reported outcomes identified in the literature review and LSDP patient-level dataset. The forum and/or interviews will then open to a facilitated group discussion where participants are given the opportunity to describe their experience with LSDP medicines and what outcomes are most important to them.

The collection and reporting of expert opinion from patients and clinicians will be conducted in accordance with guidance provided in Appendix 1 of the PBAC Guidelines v.5.0.

* 1. **Synthesis of findings**

In addressing the research questions, attempts will be made to stratify patients (where appropriate) by: age, gender, location of infusion (e.g. hospital, home or self-administered), and/or severity/disease progression.

Thematic analysis of stakeholder input gathered against each question will be undertaken to identify the most valued patient-relevant outcomes by stakeholder group. This analysis will inform research questions 1 and 2.

* 1. **Limitations**

Development and/or refinement of PROs and PRO measures (PROMs) is a highly specialised area of research. It typically involves rigorous needs analysis, conceptualisation, testing, and validation9, 10, beyond the activities to be undertaken in ToR 4. Therefore, further study may be required to test the validity of ToR 4 PROs identified as being important to LSDP patients, for instance, assessing if PROs are indeed a direct result of Fabry disease medicines under the LSDP.

Being a rare disease, Fabry disease patient populations are inherently small. As such, PROM tools to measure Fabry disease-specific PROs may not have been developed.

Requested CAG and clinician international sponsor registry data may obtain aggregate data but patient level data is unlikely.

# ToR 5: Value for money of LSDP Fabry disease medicines

This Chapter outlines the methodology that will be used to address ToR 5 *“Conduct an analysis of the value for money of LSDP Fabry disease medicines under the current funding arrangements”.*

The purpose of ToR 5 is to conduct an economic analysis assessing the costs of the medicines funded under the LSDP relative to the benefits they provide.

## Overview of data sources to inform ToR 5

To address ToR 5 an economic analysis of LSDP Fabry disease medicines funded under current arrangements will be undertaken. If findings from ToR 1 indicate that changes to the funding criteria are warranted then an economic analysis under alternate funding arrangements will also be considered. Consistent with all Government investments, an economic model will be developed, to provide Government with a standard output of value for money (e.g. QALY or ICER). Also, to ensure the ongoing sustainability of the LSDP program funded by the Australian Government an economic model will be required to investigate whether the actual costs are consistent with predicted costs as included in the initial LSDP listing. The type of economic model developed to address ToR 5 will take into consideration the availability of evidence, as identified through the review process. Table 6.1 presents the research questions to address ToR 5 and the data sources which will be used to answer each of the research questions. Details on the individual data sources are provided in Appendix A.

**Table 6.1:** **Research questions to address ToR 5**

| ToR 5 research questions | Data sources |
| --- | --- |
| Systematic literature reviewa | LSDP patient-level data | LSDP dispensing data | LSDP pricing data | PBAC submissions | MBS, PBS, AR-DRGs | Stakeholder consultation\* |
| What is the total annual cost of treating a patient with the LSDP medicines? Is this different to what was expected at the time these medicines were included on the LSDP (e.g. actual vs predicted)? | – | + | + | + | + | – | + |
| What difference in quality of life is estimated for successfully treated and untreated patients with Fabry disease? Is this different to what was expected at the time these medicines were included on the LSDP (e.g. actual vs predicted)? | + | + | – | – | + | – | – |
| What difference in survival is estimated for successfully treated and untreated patients with Fabry disease? Is this different to what was expected at the time these medicines were included on the LSDP (e.g. actual vs predicted)? | + | + | – | – | + | – | – |
| Is there a difference in costs or outcomes associated with each of the two LSDP medicines? | + | + | + | + | + | +  | + |
| How do the costs and outcomes associated with each of the LSDP medicines compare with the costs and outcomes of standard of care? | + | + | + | + | + | +  | + |

Abbreviations: AR-DRGS, Australian Refined – Diagnosis Related Groups; LSDP, Life Saving Drugs Program; MBS, Medicare Benefits Schedule; PBS, Pharmaceutical Benefits Schedule; PBAC, Pharmaceutical Benefits Advisory Committee

**a** Includes HTA websites \* only required if other data sources do not yield the required information

The following sections explain how each of the identified data sources will be used to inform the analysis undertaken for each of the research questions.

## Systematic Literature Review

Two systematic literature reviews (described under Table 6.2) will be conducted to source information for ToR 5. These systematic literature reviews will focus on economic evaluations and quality of life. Table 6.2 summarises the literature search criteria that will be used to address ToR 5. The search strings used in the literature search criteria are based on Canadian Agency for Drugs and Technologies in Health’s (CADTH) Database Search Filters.11 The relevant PubMed search string can be found in Appendix D (refer to Section D.5). Further detail on the systematic review methodology is provided in Appendix B.

**Table 6.2: Literature search criteria for ToR 5**

|  |  |
| --- | --- |
| **Limit** | **Eligibility criteria** |
| Search terms | * Synonyms for Fabry disease and an appropriate filter to identify economic evaluations and quality of life measures will guide the search. Details of the terms are provided in Section D.5 of Appendix D.
 |
| Databases | * EMBASE
* Medline
* Tufts Medical Centre CEA Registry
* University of York Centre for Reviews and Dissemination
* Health Economic Evaluations Database (HEED)
 |
| Other means to identify relevant information | * Websites of HTA and reimbursement agencies: NICE, CADTH, SMC
* Manual scan of reference lists of included articles
 |
| Publication types | * Full text systematic reviews, literature reviews, clinical trial publications, economic evaluation reports, and reimbursement application reports
* Available in English
 |
| Search period | * Articles published from 2012a
* Conference abstracts published since 2017b
 |
| Study exclusion criteria | * Does not relate to patients with Fabry disease
* For the search of economic evaluations: Does not include an economic model
* For the search on quality of life: Does not include quality of life scores
 |

Abbreviations: ToR, Term of Reference; CEA, Cost-Effectiveness Analysis; HTA, Health Technology Assessment; NICE, National Institute for Health and Care Excellence; CADTH, Canadian Agency for Drugs and Technologies in Health; SMC, Scottish Medicines Consortium, HEED, Health Economic Evaluations Database

**a** Search will be restricted from 2012 to identify any new evidence since the last LSDP 2015 published report with a 3-year retrospective evidence retrieval and evaluation

**b** Conference abstracts/posters subject to a two-year restriction to allow for manuscript publication of current evidence

1. An economic evaluation requires articulation of health states that reflect the key possible clinical presentations of Fabry disease. The first search of peer-reviewed literature, including EMBASE, Medline, Tufts Medical Centre CEA Registry, the University of York Centre for Reviews and Dissemination and the Health Economic Evaluations Database (HEED) will be conducted in order to identify economic evaluations in Fabry disease.

To supplement these database searches, the HTA agency websites of the National Institute for Health and Care Excellence (NICE), the CADTH, and the Scottish Medicines Consortium (SMC) will be searched for relevant economic evaluations. Past submissions to the PBAC and LSDP for Fabry disease will also be reviewed. The purpose of these searches is to use existing published work to inform the development of the economic evaluation for this review, including the health states of the model, and structural variables such as cycle length and time horizon.

Any models sourced from the literature will be assessed based on their relevance to the funding of LSDP medicines. In particular the health states employed in the economic evaluation should be consistent with the major clinical complications of Fabry disease. If none of the models identified are appropriate for the review, health states and outcomes will be identified from the clinical literature and an economic evaluation will be constructed which is consistent with PBAC guidelines. The results of this literature review will address research question 1 of this ToR and will subsequently be used in the development of the economic model for research question 4.

* 1. The second search will seek to identify information on mortality and quality of life for patients with Fabry disease. A systematic literature review on the impact of LSDP treatment on mortality and quality of life is being undertaken to address ToR 3. Therefore, those results will be considered prior to any additional search being undertaken for ToR 5. This search will inform research questions 2, 3, 4 and 5.

Quality of life outcomes will be modelled by using peer-reviewed literature to assign utility values to the health states of the model. An alternative methodology will involve mapping quality of life scores to SF-36 physical component score (PCS) and mental component score (MCS) using the LSDP patient-level data. The literature search conducted for quality of life measures will identify publications reporting utility values for the desired health states, or methodologies for mapping the SF-36 to utility values. Both methodologies will be used to address research question 2.

## LSDP patient-level data

The LSDP patient-level data will be analysed to inform what non-LSDP medicines are used in the treatment of Fabry disease. The use of medicines unrelated to Fabry disease will be distinguished from those that are related by consulting with clinicians regarding which non-LSDP medicines they use to manage the symptoms and complications of the disease. Medicines not related to the treatment of Fabry disease will be excluded from the modelled economic evaluation.

The list of concomitant medicines for each Fabry disease patient will be used to calculate the amount of drug use for the average patient on treatment with LSDP medicines. This resource will be used to address research question 1 of ToR 5 and subsequently in research questions 4 and 5.

In addition to the list of concomitant medicines to be generated from patient level data from the LSDP program, available SF-36, PCS and MCS will be mapped to utility scores to address research question 2.

## LSDP dispensing data

The LSDP dispensing data will be used to calculate how much of the drug was dispensed to each patient in order to calculate the cost of treating a patient for a year. This will be used to address research question 1 and to construct the economic evaluation for research questions 4 and 5.

## LSDP pricing data

The unit costs obtained from the LSDP pricing data will be used to calculate the total cost of LSDP medicines per patient. This analysis will be conducted separately for each Fabry disease medicine on the LSDP. The cost of treating a patient using LSDP medicines will be used to inform research questions 1, 4 and 5.

## PBAC submissions

The approach to the economic evaluation taken in previous submissions to the PBAC or LSDP will be considered in the development of the economic evaluation. This will include the type of economic evaluation (e.g. cost-effectiveness or cost-utility), computational methods (e.g. Markov process, microsimulation, decision tree), time horizon, and any other relevant parameters. Any issues the PBAC had with the economic evaluations presented will also be considered.

## MBS, PBS, AR-DRG cost weights and National efficient price data

Unit costs for resources used in the management of Fabry disease will be sourced in accordance with guidance contained in the Manual of resource items and their associated unit costs.12 For example, the MBS schedule will be used to source unit costs for medical services, the PBS schedule will be used to source unit costs for medicines, and AR-DRG cost weights and the national efficient price will be used to source unit costs for episodes of hospitalisation. Unit costs will be used to address research questions 1, 4 and 5.

## Stakeholder consultation (if required)

If values for inputs to the economic evaluation cannot be sourced from evidence from higher levels in the hierarchy of evidence (as described in Sections 6.2 to 6.7), expert opinion will be sought. The collection and reporting of expert opinion from patients and clinicians will be conducted in accordance with guidance provided in Appendix 1 of the PBAC Guidelines v.5.0.6 Expert opinion may include data obtained through surveys undertaken by Fabry Australia that collected clinician time; data from the ANZDATA (including pre-2002 or kidney function at time of starting LSDP compared to projection with ANZDATA); and/or CAG/clinician international sponsor registry aggregate data.

## Synthesis of findings

The economic evaluation will be constructed and reported in accordance with the guidance provided in the PBAC guidelines6, which specify the elements of the full economic model to be presented. We will present:

* the type of economic evaluation, computational methods, and health states
* the costs associated with the treatment options, and
* the quality of life for patients with Fabry disease.

Research questions 4 and 5 will be addressed by integrating information assembled in addressing the previous research questions. Costs and outcomes for LSDP-eligible patients treated with agalsidase alfa, agalsidase beta, and for standard of care will be reported. Standard of care will be clearly defined, this may include ERT or non-specific standard of care therapies. Pair-wise comparisons will be developed to compare treatment options against each other. The 2015 Review will be consulted for any information relevant to the development of the economic evaluation.

Validation will be performed as per the PBAC guidelines.6 Internal validation will be performed by using traces to examine the flow of patients through the model, and checking the change in the final results due to changes in other model parameters to ensure that the logic of the model is correct. External validation will be performed by comparing the model traces and results with empirical data and by comparing the model to other valid modelled economic evaluations of Fabry disease. Inclusion of indirect costs in economic models (e.g. days off work, missed school, carer burden etc) and societal perspective economic evaluations are not accepted by PBAC. However this review will seek to gather narrative on these issues through the stakeholder consultations so that they can be included in the discussion of value for money in the Review Report.

## Limitations

The most significant limitation in ToR 5 is that the clinical evidence may not be sufficient to produce a high-quality economic evaluation or to allow for meaningful external validation. The validity of any economic evaluation depends on the quality of the evidence. In the case of Fabry disease, it is likely that relatively few clinical studies exist, and the ones that have been conducted are likely to have recruited low numbers of patients. An additional issue is that modelling of surrogate outcomes to patient-relevant outcomes such as mortality and quality of life may be required. Such modelling may decrease confidence in the results of the economic evaluation. These limitations may impact important elements of the economic evaluation, such as the outcome to be modelled, which cannot be decided on until the clinical evidence is reviewed. These decisions will be based on the quality of the evidence uncovered during the review and discussion with the LSDP Expert Panel.

# ToR 6: Utilisation of LSDP Fabry disease medicines

This Chapter outlines the methodology that will be used to address ToR 6 *“Review the utilisation of LSDP Fabry disease medicines, including the way they are stored and dispensed, and evidence of patient compliance to treatment”.*

The purpose of ToR 6 is to review how LSDP funded medicines are used to ensure quality use of medicines. This includes analysing patient doses, duration of treatment, switching between medicines and patient compliance.

## Overview of data sources to inform ToR 6

To address ToR 6, a review of the utilisation of LSDP Fabry disease medicines, including the way they are stored and dispensed, and evidence of patient compliance to treatment, will need to be undertaken. Table 7.1 presents the research questions to address ToR 6 and the data sources which will be used to answer each of the research questions. Details on the individual data sources are provided in Appendix A.

**Table 7.1: Research questions to address ToR 6**

| ToR 6 research questions | Data sources |
| --- | --- |
| Systematic literature reviewa | LSDP patient-level data | LSDP dispensing data | LSDP pricing data | PBAC submissions | Stakeholder consultation |
| Utilisation |  |  |
| How many patients (by treatment, by year and in total) have been treated under the LSDP? How does this compare with expectations at the time these medicines were included on the LSDP? | - | + | + | - | + | - |
| How many units (by treatment, by year and in total) have been dispensed under the LSDP? How does this compare with expectations at the time these medicines were included on the LSDP? | - | + | + | - | + | - |
| What is the expenditure (by treatment, by year and in total)? How does this compare with expectations at the time these medicines were included on the LSDP? | - | + | + | + | + | - |
| What is the rate of change in patient numbers, units, and expenditure year on year and overall? How does this compare with expectations at the time these medicines were first included on the LSDP? | - | + | + | + | + | - |
| Has there been utilisation beyond the eligibility criteria? | + | + | + | - | + | + |
| Does the utilisation data reflect the approved therapeutic relativity? | + | + | + | - | + | - |
| What quantity and value of LSDP medicine is wasted? Has this changed over time? | - | - | + | + | - | - |
| Compliance |  |  |  |  |  |  |
| What is the average duration (and distribution around duration) of treatment? How does this compare across these medicines? | - | + | + | - | - | + |
| What is the average dose (and distribution around average dose)? How does this compare to the approved\* use and across medicines? | + | + | + | - | + | + |
| What is the average interval between doses (and distribution around this interval)? How does this compare to the approved use and across medicines? | + | + | + | - | - | + |
| Have patients had treatment breaks? If so, what proportion of patients and why? How does this compare across medicines? | + | + | + | - | - | + |
| Has there been switching between treatment? If so, why? | - | + | + | - | - | + |
| Drug storage |  |  |
| Is there variation in storage and dispensing processes by drug custodians (e.g. pharmacies or administrators)? | + | - | + | - | - | + |

Abbreviations: LSDP, Life Saving Drugs Program; PBAC, Pharmaceutical Benefits Advisory Committee

**a**Includes Product Information, \* Regulatory (such as TGA) and LSDP approved doses

As part of addressing the research questions above, the analysis will examine trends on compliance by age, gender, location etc for each question. The following sections explain how each of the identified data sources will be used to inform the analysis undertaken for each of the research questions.

## Systematic literature and documentation review

A systematic literature review will be conducted to inform patient compliance with Fabry disease medicines. Information sought will be on appropriate dosage schedules and usage outside of guidelines. Table 7.2 presents the search strategy. The relevant PubMed search string can be found in Appendix D (refer to Section D.6). Further detail on the systematic review methodology is provided in Appendix B.

**Table 7.2: Literature search criteria for ToR 6**

|  |  |
| --- | --- |
| **Limit** | **Eligibility criteria** |
| Search terms | * Synonyms for Fabry disease and an appropriate filter to identify publications on treatment compliance will guide the search. Details of the terms are provided in Section D.6D.5 of Appendix D.
 |
| Databases | * EMBASE
* Medline
* Cochrane library
 |
| Other means to identify relevant information | * PBAC PSDs
* Manual scan of reference lists of included articles
* Medicine Product Information (TGA)
* LSDP documents (Australian Government Department of Health)
 |
| Publication types | * Full text systematic reviews, literature reviews, clinical trial publications, and reimbursement application reports
* Available in English
 |
| Search period | * Articles published from 2009a
* Conference abstracts published since 2017b
 |
| Study exclusion criteria | * Does not relate to patients with Fabry disease
 |

Abbreviations: PBAC, Pharmaceutical Benefits Advisory Committee; PSD; Public Summary Document

**a** Search will be restricted from 2009 as ToR previously not seen by LSDP

**b** Conference abstracts/posters subject to a two-year restriction to allow for manuscript publication of current evidence

In addition to the systematic literature review, product information (PI) for both Fabry disease medicines will be obtained from the TGA website. Dosage and administration information from the PI will be compared against the real-world use of medicines available in the LSDP dispensing data (refer to Section 7.4). This comparison will enable an analysis to be made of how compliant LSDP patients are to treatment to inform research questions 9 and 10 as well as identification of treatment breaks to inform research question 11. Information from the LSDP eligibility criteria for Fabry disease will be used to address research question 5. Information regarding the therapeutic relativity between agalsidase alfa and agalsidase beta will be obtained from clinical studies, PBAC submissions, and the LSDP guidelines for applications to address research question 6. Finally, information from the Presentation and Storage Conditions section of the PI will be used to describe the intended way the medication should be stored by medicine custodians and will inform research question 13.

## LSDP patient-level data

The LSDP patient-level data and dispensing data will be linked by a unique identifier for each patient. This will allow the examination of any relationship between changes in clinical variables and dosing. LSDP patient-level data will be used to understand reasons for any change in the use of medications. Reasons which may be identified through the LSDP patient-level data may include disease progression, reduction in the clinical effectiveness of treatment, and adverse events. The level of antibodies to treatment, levels of substrates, and clinical indicators of disease severity may be included in clinical notes. Any additional information included in clinical notes will be analysed to address research questions 1 to 6 and 8 to 12 concerning patient compliance, treatment switching, and utilisation (including beyond progression).

## LSDP dispensing data

Two variables in the LSDP dispensing dataset will be used to inform the research questions in ToR 6:

1. The number of days between dispensing will be used to inform research question 10. A mean, standard deviation, median, and inter-quartile range will be calculated to provide detail on the variability of the interval between dosing across the entire LSDP.

To inform research question 11, the interval between dosing will be compared with the dosage regimen from the literature.

* 1. The dispensed amount will be calculated using the vial strength and the number of vials dispensed on each occasion. Summary statistics will be produced for the dispensed amount. This will be compared with the prescribed dose, as well as product information to assess whether the actual use of the medicine complies with the approved use. This will also allow identification of any medication wastage, a breakdown of annual wastage costs, and analysis of therapeutic relativity between the Fabry medicines by examining relative usage levels. Identifying the amount of medicine patients receive, including whether patients are on treatment at all, will be used to address every research question within ToR 6.

## LSDP pricing data

The unit costs from the LSDP pricing data will be used to calculate the cost of LSDP medicines dispensed over the period of funding. This will be compared to the financial projections at the time of listing to address research question 3 and the rate of change will be calculated to address research question 4. To calculate the amount of wastage and address research question 7, the total cost of the program will be compared with the amount which would be spent if exactly the correct quantities of the medicine could be dispensed. These wastage calculations will supplement the value for money calculations in ToR 5.

## PBAC submissions

The estimated number of patients that will use the medicine, the unit costs, and the total cost of funding over five years will be extracted from the financial estimates in Section 4 of the relevant PBAC submissions. The number of patients and total cost of providing the medicine will be compared between the real-world costs (based on LSDP dispensing and pricing data) and the initial projections. It will be determined whether the difference between the two is due to a discrepancy in the total number of patients, the number of patients on each medicine, the number of units of the medicine dispensed, or the unit cost of the medicines. Other than for direct comparison to the projections at the time of funding, the PBAC submissions may also give insight into the process of deciding upon criteria such as eligibility and maximum dosing. This data will be used to address research questions 1 to 6, and 9.

## Stakeholder consultation

Stakeholders may be approached to fill any information gaps identified within the utilisation assessment. This consultation may occur by approaching specific stakeholders directly or through administration of an online survey. Again, the use of expert opinion to address the research questions in the review will follow the methods described in Appendix A of the PBAC guidelines. The content of these questions will focus on the reasons for the utilisation behaviour observed in the dispensing data and any issues with compliance.

## Synthesis of findings

To address the research questions related to utilisation (research questions 1 to 7), LSDP dispensing data and LSDP pricing data will be used to create a budget impact analysis calculating the number of patients on each LSDP medicine, the amount of medicine used in each year, the unit cost of each dose, and the total cost to the LSDP for each year. Actual costs using LSDP data will be compared to projected costs from the historical PBAC submissions. To address research question 5, LSDP patient-level data and dispensing data will be interrogated to identify patients whose disease has progressed to the point where ERT is no longer a suitable treatment. Stakeholder input will be used if the LSDP datasets are not sufficient for this purpose. The criteria which define whether a patient is no longer suitable for ERT will be based on the exclusion criteria from the Fabry disease guidelines.7 For research question 6 (does utilisation reflect the approved therapeutic relativity?), the utilisation identified to address the earlier research questions will be compared with the approved dosages from the LSDP guidelines7. For research question 7 (wastage), real-world utilisation will be compared with the modelled situation where it is possible to dispense the exact required dosages.

Comparative analysis will also be conducted for each outcome specified in research questions 1 to 4. For example, the average dose will be compared between medications to assess whether compliance to treatment differs depending on the medication. If data is available the treatment setting (e.g. home, hospital etc) in which administration of the LSDP medicine occurs and/or postcode of the location where administration occurs and/or home postcode of patient will be analysed to assess if any of these variables have an impact on medicine utilisation and/or compliance.

To address the research questions related to compliance (research questions 8 to 12), LSDP dispensing data will be analysed to assess the duration of treatment, average dose, interval between dosing (including breaks from treatment), and treatment switch. This will be compared to the PIs in order to assess whether practice is compliant with the approved use of the medicines. The systematic literature review will be used to inform the findings on patient compliance to treatment and supplemented by qualitative data gathered through stakeholder consultation process. Analysis of stakeholder input will be used to inform the reasons for any dosing deviations.

To address drug storage, stakeholder input will be sought to determine how LSDP medicines are stored at various points between reception at the pharmacy and administration. Thematic analysis of the stakeholder input will be compared with directions on storage and handling from the product information. This will inform research question 13 by determining whether users are handling the medicines appropriately.

## Limitations

The most significant limitation in ToR 6 is the quality of the LSDP datasets. ToR 6 involves in depth analysis of the LSDP patient-level and dispensing datasets to identify information which addresses the research questions. Any gaps in the data will impact our ability to inform and/or validate the data against each of the research questions. For research question 5 (utilisation of medicines beyond the eligibility criteria) for example, it may not be possible to identify when disease progression has occurred from the LSDP patient level or dispensing data. It is also important to place suitable parameters to define treatment breaks in the analysis of patient compliance. Where analyses are unable to be conducted or if we are not confident in the validity of the results due to data quality issues, this will be noted, and suggestions will be made regarding how to address these issues at the system-level in the future.

# ToR 7: Developing technologies that may impact future access

This Chapter outlines the methodology that will be used to address ToR 7 *“Investigate developing technologies that may impact future funded access”.*

The purpose of ToR 7 is to identify what treatments and/or testing methodologies, if any, are emerging for Fabry disease and what impact (if any) this could have on the administration of the program going forward.

* 1. **Overview of data sources to inform ToR 7**

To address ToR 7, a horizon scan of developing technologies and innovations that may impact future access (i.e. within the next five years) to LSDP Fabry disease medicines will be undertaken. For the purpose of the scan, technologies are defined as emerging treatments and testing methodologies. Table 8.1 presents the research questions to address ToR 7 and the data sources which will be used to answer each of the research questions.

**Table 8.1: Research questions to address ToR 7**

| **ToR 7 research questions** | **Data sources** |
| --- | --- |
| **Peer-reviewed literature databases** | **Early assessment and alert systems** | **HTA / research organisations** | **Regulatory agencies** | **News** | **Clinical trials registries** | **Other sources** |
| 1. What new treatments are emerging and how are they to be used?
 | + | + | + | + | + | + | + |
| 1. What new patient testing methodologies are being developed / adopted / promoted?
 | + | + | + | + | + | + | + |
| 1. What is the potential impact of developing technologies on the LSDP?
 | + | + | + | + | + | + | + |

Horizon scans are implemented to detect emerging healthcare technologies and innovations and inform stakeholders. Identified technologies and innovations undergo rapid assessment and are prioritised based on their potential impact for patients and the healthcare system. Consequently, these could impact on future access. Furthermore, identified technologies and innovations could have the ability to impact the administration of the LSDP. This could be due to the identification of extra patients, see more usage, thus, increasing government expenditure. Potentially significant technologies and innovations will be assessed in terms of their effectiveness, cost, safety, impact to the health system and ethical considerations.

The following sections explain how each of the identified data sources will be used to inform the analysis undertaken for each of the research questions.

* 1. **Peer-reviewed literature**

A search of the literature for new and emerging pharmaceuticals and testing methodologies relevant to Fabry disease will be conducted using:

1. Peer-reviewed databases: Cochrane, PubMed, and Embase.com. The PubMed search terms are provided in Table 8.2. The databases will be searched using Boolean logic and the syntax unique to each database
	1. The selected sources given in Appendix E will also be reviewed for new medicines or molecules for rare diseases and conditions. Further detail on the systematic review methodology is provided in Appendix B.

**Table 8.2: Literature search criteria for ToR 7**

| **Parameter** | **Search terms and limits** |
| --- | --- |
| Search terms | * Synonyms for Fabry disease and an appropriate filter to identify clinical guidelines will guide the search. Details of the terms are provided in Appendix D.
 |
| Limits | * English and reputable trials not published in English AND humans
 |
| Search period | * Articles published from 2012a
* Conference abstracts published since 2017b
 |

**a** Search will be restricted from 2012 to identify new and current treatment modalities

**b** Conference abstracts/posters subject to a two-year restriction to allow for manuscript publication of current evidence

The sources shown in Table E-1 located in Appendix E (also summarised in Sections 8.3-8.8), will be searched using the same terms. However, searches will be varied using single terms, phrases, or combinations of these due to the search limitations that each source allows. A simpler approach is likely required for sources that use a search engine platform, although advanced searches will be used if the option is available. The horizon scan seeks to determine the impact of technologies and innovations that are likely to emerge within the next three to five years. Given the lag time in regulatory submissions between Europe, American and Australia, the horizon scan will search for papers from 2017 to account for this.

* 1. **Early assessment and alert systems**

Three different sources that specialise in scanning for future treatments will be utilised as described in Appendix E. By using these sources, incoming technologies can be detected and analysed for their potential impact on future access and usage of Fabry disease treatments. By using three different sources it is believed that information will likely be corroborated or further supported, allowing for better analysis. Additionally, by using multiple sources, exclusive findings and publications can also be detected.

* 1. **HTA/independent research organisations**

Several different HTA agencies and research organisations will also be sourced to determine the impact of impending technologies on future access as described in Appendix E. Given the nature of these organisations, emerging technologies will have gone through an assessment with their impact assessed for a foreign healthcare system. However, the benefits of novel technologies are likely to be identified and communicated in their publications. These findings will also be used in assessing for the impact of developing technologies on future access of Fabry disease treatments.

* 1. **Regulatory agencies**

Three main agencies (EMA, FDA and TGA) will also be reviewed. By researching these agencies, technologies that are likely to be commercially available in Australia within the next three to five years can also be identified. From the reports obtained, information such as efficacy and safety data can also be presented to inform the impact of developing technologies on future access for Fabry disease patients.

* 1. **News**

News websites specialising in healthcare, pharmaceutical and testing technologies will be researched for any developing innovations as described in Appendix E. Furthermore, other commercially available products that could impact Fabry disease patients but may not necessarily go through the traditional regulatory and HTA route can also be identified. The potential impact of new innovations on Fabry disease patient numbers, usage of medications and government expenditure will also be analysed. Lastly, news websites can also be used to corroborate on findings from other data sources but also report on exclusive news.

* 1. **Clinical trial databases**

Four main clinical trial registries will be reviewed to identify developing technologies that could impact future access for Fabry disease patients as described in Appendix E. These databases will be used to identify novel therapeutic agents that may be submitted to a regulatory agency as well as an HTA agency. Clinical trial databases will also identify developing technologies from Phase I to IV but also provide a synopsis on the type of technology used (e.g. chaperone/gene/substrate reduction therapy).

* 1. **Other**

Other resources, as described in Appendix E, will also be investigated not only to corroborate findings from the other five major sources but also identify any other missing pieces of information that could impact on the assessment of developing technologies on future access of Fabry disease treatments.

Also, stakeholders consulted as part of the other ToR, will be asked whether they are aware of any new treatments and/or patient testing methodologies, and what impact if any, they believe they will have on the LSDP over the next five years.

* 1. **Synthesis of findings**

Identified developing health technologies will be presented according to their category (e.g. treatment or test). Categories of findings will be discussed, with detail provided for new technologies. Where possible, the likelihood of emergence of the new technology in the near future will be assessed. Particular types of new and emerging technologies will be reviewed briefly in which the following will be included:

* Introduction (Brief background)
* Intervention (What is the technology? How does it work?)
* Comparators (What other options are available?)
* Where will the intervention fit in the management algorithm for Fabry disease?
* What are the characteristics of the population in whom it is being studied?
* Effectiveness (How well does the technology reach its outcomes?)
* Safety
* Cost impact
* Ethical cultural or religious considerations
* List of studies/references

In addition to these criteria, a summary sheet will be completed (Appendix E, Table E-2). The goal of the summary sheet is to provide a synopsis of the identified technology, in addition to its clinical and regulatory progress to date. The table will also address the other criteria listed above where possible.

By addressing these topics, the identified technology’s impact on: a patient’s life expectancy; quality of life; whether alternative treatments are available; and the Australian health system can be reviewed. Technologies to emerge within the next three years will be presented and discussed. Any medicines that are not expected to emerge within this time frame (e.g. medicines for which only animal studies are available) will not be reviewed.

# References

1. Australian Government. Department of Health Acronyms and Glossary. <http://www.health.gov.au/internet/main/publishing.nsf/content/glossary>.

2. Sanofi Genzyme RegistryNXT. <https://www.registrynxt.com/>.

3. ClinicalTrials.gov, Fabry Disease Registry. 2018.

4. Shire *Fabry Outcome Survey Annual Report*; 2016.

5. Australian Governemt. The Pharmaceutical Benefits Advisory Committee (PBAC), Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee. 2016.

6. Australian Government. Department of Health, Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee. Version 5.0. 2016.

7. Australian Government. Department of Health, Life Saving Drugs Program (LSDP) guidelines for initial application and annual reapplication for subsidised treatment for Fabry disease. 2018.

8. Australian Commission on Safety and Quality in Health Care Patient-Reported Outcome Measures. <https://www.safetyandquality.gov.au/our-work/indicators/patient-reported-outcome-measures/>.

9. Rothrock, N. E.; Kaiser, K. A.; Cella, D., Developing a valid patient-reported outcome measure. *Clin Pharmacol Ther* **2011,** *90* (5), 737-42.

10. Deshpande, P. R.; Rajan, S.; Sudeepthi, B. L.; Abdul Nazir, C. P., Patient-reported outcomes: A new era in clinical research. *Perspect Clin Res* **2011,** *2* (4), 137-44.

11. Canadian Agency for Drugs and Technologies in Health (CADTH) Strings Attached: CADTH's Database Search Filters. <https://www.cadth.ca/resources/finding-evidence/strings-attached-cadths-database-search-filters#guide> (accessed 21 January 2019).

12. Australian Government. Department of Health, Manual of resource items and their associated unit costs. Version 5.0. 2016.

13. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D. G.; Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* **2009,** *151* (4), 264-9, W64.

14. Coleman, K.; Norris, S.; Weston, A.; Grimmer-Somers, K.; Hillier, S.; Merlin, T.; Tooher, R. J. C. N., NHMRC additional levels of evidence and grades for recommendations for developers of guidelines. **2005**.

15. Shea, B. J.; Reeves, B. C.; Wells, G.; Thuku, M.; Hamel, C.; Moran, J.; Moher, D.; Tugwell, P.; Welch, V.; Kristjansson, E. J. b., AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. **2017,** *358*, j4008.

16. Guyatt, G.; Oxman, A. D.; Akl, E. A.; Kunz, R.; Vist, G.; Brozek, J.; Norris, S.; Falck-Ytter, Y.; Glasziou, P.; Jaeschke, R. J. J. o. c. e., GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. **2011,** *64* (4), 383-394.

17. Balshem, H.; Helfand, M.; Schünemann, H. J.; Oxman, A. D.; Kunz, R.; Brozek, J.; Vist, G. E.; Falck-Ytter, Y.; Meerpohl, J.; Norris, S. J. J. o. c. e., GRADE guidelines: 3. Rating the quality of evidence. **2011,** *64* (4), 401-406.

18. Consortium, A. N. S. The AGREE II Instrument [Electronic version]. <https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf> (accessed 24 January 2019).

19. Higgins, J.; Sterne, J.; Savović, J.; Page, M.; Hróbjartsson, A. J. C. D. o. S. R., A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V (editors). Cochrane Methods. **2016,** *10*.

20. Germain, D. P., Fabry disease. *Orphanet J Rare Dis* **2010,** *5*, 30.

21. Zarate, Y. A.; Hopkin, R. J., Fabry's disease. *Lancet* **2008,** *372* (9647), 1427-35.

22. Australia, P. A. Fabry Disease: The Genetic Condition You've Probably Never Heard Of. <https://knowpathology.com.au/2018/04/27/fabry-disease/>.

23. Ellaway, C., Paediatric Fabry disease. *Transl Pediatr* **2016,** *5* (1), 37-42.

24. Australian Government. Department of Health Life Saving Drugs Program - Information for patients, prescribers and pharmacists. <http://www.health.gov.au/internet/main/publishing.nsf/Content/lsdp-criteria>.

25. Laney, D. A.; Bennett, R. L.; Clarke, V.; Fox, A.; Hopkin, R. J.; Johnson, J.; O’Rourke, E.; Sims, K.; Walter, G. J. J. o. g. c., Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. **2013,** *22* (5), 555-564.

26. Sandra Sirrs, D. G. B., R. Mark Iwanochko, Aneal Khan, David Moore, Gavin Oudit and Michael L. West, Canadian Fabry Disease Treatment Guidelines 2017. **2017**.

27. Therpautic Goods Administration, Product Information Fabrazyme. 2017.

28. Therpautic Goods Administration, AUSTRALIAN PRODUCT INFORMATION REPLAGAL (agalsidase alfa ghu). 2018.

29. Therpautic Goods Administration, Australian Public Assessment Report for migalastat,. Health, D. o., Ed. 2018.

30. Therpautic Goods Administration PRODUCT INFORMATION – Galafold®. <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-02361-1> (accessed 25 January 2019).

31. Government, A., Medicine for rare disease made free on the Life Saving Drugs Program. *Media Release* **Accessed: 1 November 2018,** (Galafold® (migalastat) ).

32. Australian Government. Therapeutic Goods Administration, Australian Public Assessment Report for migalastat. **2018**.

33. Australian Government. Therapeutic Goods Administration, Australian Product Information: Replagal (agalsidase alfa ghu). 2018.

34. Australian Government. Therapeutic Goods Administration, Product Information: Fabrazyme. 2017.

35. Australian Government. Pharmaceutical Benefits Advisory Committee, Updated literature review of agalsidase alfa (Replagal) and agalsidase beta (Fabrazyme) for the treatment of Fabry disease. 2009.

36. Mehta, A.; Beck, M.; Eyskens, F.; Feliciani, C.; Kantola, I.; Ramaswami, U.; Rolfs, A.; Rivera, A.; Waldek, S.; Germain, D. P., Fabry disease: a review of current management strategies. *QJM* **2010,** *103* (9), 641-59.

: Description of data sources

LSDP Patient-level data

LSDP patient-level data is collected annually for all patients on the LSDP through the initial and annual reapplication for LSDP subsidised treatment for Fabry disease.

Through the LSDP, the Australian Government provides subsidised access for eligible patients to expensive lifesaving medicines. Treating physicians with relevant specialist registration who wish to apply for their patients to receive access to Australian Government subsidised treatment for Fabry disease through the LSDP are required to complete criteria for general, initial and ongoing eligibility to access subsidised treatment.

The treating physician must submit the reapplication form to the LSDP by 1 May every year if they wish their patients to continue to receive subsidised treatment through the LSDP.

The reapplication form must demonstrate clinical improvement in the patient or stabilisation of the patient's condition, and evidence to support ongoing eligibility for the treatment of Fabry disease must be provided.

The treating physician must declare that the patient continues to meet the eligibility criteria to receive subsidised treatment through the LSDP in accordance with the guidelines.

For Fabry disease, a patient must:

1. satisfy the initial and ongoing eligibility criteria as detailed below;
	1. participate in the evaluation of effectiveness of the drug by periodic assessment, as directed by these Guidelines, or have an acceptable reason not to participate;
	2. not be suffering from any other medical condition, including complications or sequelae of Fabry disease, that might compromise the effectiveness of the drug treatment; and
	3. be an Australian citizen or permanent Australian resident who qualifies for Medicare.7

LSDP patient-level data collected annually for patients on the LSDP receiving Fabry disease treatment agalsidase alfa and agalsidase beta is presented in Table A-1.

Table A-1: LSDP data collected annually from Fabry disease patients

|  |
| --- |
| **Patient Level Program Data**  |
| **Demographics** |
| Age (years) |
| Gender |
| Height (m) |
| Weight (kg) |
| Blood pressure (mmHg) |
| **Laboratory tests** |
|  |
| Urea |
| Creatinine |
| eGFR |
| Fasting total cholesterol |
| Fasting LDL cholesterol |
| Fasting HDL cholesterol |
| Plasma lysoGB3 |
| Plasma GB3 |
| **Hearing test** |
| **Respiratory function tests** |
| **Urinalysis** |
|  |
| Urine protein excretion |
| Protein:creatinine ratio |
| Urine albumin excretion |
| Albumin:Creatinine ratio |
| **Cardiac** |
|  |
| ECG |
| Echocardiogram (Cardiac wall thickness -interventricular septum or left ventricular posterior wall) |
| Cardiac MRI (cardiac mass or normalised cardiac mass) |
| Baseline electrophysiological study (for patients with short PR interval) |
| Myocardial biopsy (in patients with LVH) |
| **Renal** |
| GFR (measured by nuclear medicine scan) |
| Renal biopsy (for selected patients) |
| **Cerebrovascular** |
| Cranial Brain Image (MRI) |
| Standardised neurological examination (including temperature and vibration sensation) |
| **Pain (for patients qualifying under pain criteria)** |
| Pain diary (preferred) |
| Pain score - Brief Pain Inventory (note: pain diary preferred) |
| Summary from Physician (for selected patients)  |
| **Quality of Life score (PCS, MCS)** |
| **Concurrent medications and doses** |

Source: Australian Government Department of Health. Accessed 2019. Life Saving Drugs Program (LSDP) guidelines for initial and annual reapplication for subsidised treatment for Fabry disease.

Abbreviations: ECG, electrocardiogram; eGFR, estimated Glomerular filtration rate; GB3, globotriaosylceramide; GFR, Glomerular filtration rate; HDL, high-density lipoproteins; kg, kilogram; LDL, low-density lipoproteins; LVH, Left ventricular hypertrophy; m, meters; MCS, mental component score; mmHg, millimetres of mercury; MRI, Magnetic resonance imaging; PCS, Physical component score

LSDP dispensing data

LSDP dispensing data is collected continuously throughout the year for all patients on the LSDP receiving subsidised access to medications.

A pharmacist who is nominated by the treating physician to receive and dispense LSDP medications is designated as an ‘Authorised Person’ and has a range of responsibilities regarding the LSDP stock. These responsibilities include receiving the stock, confirming that it is in good condition, ensuring that the stock is handled in accordance with the TGA-approved product information, checking the expiry date, and notifying the Department if the patient is enrolled in a clinical trial or has ceased treatment.

A major responsibility is that pharmacists are required to maintain a dispensing record for each patient. This record is based on a template provided by the Department and if a dispensing record is not provided when requested, the Department is unable to place an order for that particular patient. The Department audits these details approximately every three months to review patient compliance and determine future supply requirements.

The information included in these dispensing records for patients on the LSDP receiving Fabry disease treatments agalsidase alfa and agalsidase beta is presented in Table A-2.

Table A-2: LSDP dispensing data collected from Fabry disease patients

|  |
| --- |
| **LSDP Dispensing Data**  |
| **Identifying information** |
| Patient identifier (e.g. X01) |
| Date of birth |
| Age |
| Month on the program |
| Year on the program |
| **Dispensing information** |
| Date of dispensing |
| Date of infusion |
| Number of days between dispensings |
| Prescribed dose |
| Dispensed amount (5mg vial) |
| Dispensed amount (35mg vial) |
| Dispensed amount (mg) |
| Amount discarded (mg) |
| Cost of discarded amount |
| Dispensing pharmacy |
| Comments |

Source: Australian Government Department of Health. Accessed 2019. Life Saving Drugs Program (LSDP) Fabry dispensing records.

LSDP pricing data

The LSDP pricing data includes details on the arrangement between the Department and the pharmaceutical companies that own the medications for Fabry disease. The data collected regarding the pricing of LSDP medications is presented in Table A-3.

Table A-3: LSDP pricing data for Fabry disease medications

|  |
| --- |
| **LSDP Pricing Data**  |
| **General information** |
| Medicine (i.e. agalsidase alfa, agalsidase beta) |
| Date of funding |
| Sponsor |
| Deed expiry date |
| Number of patients |
| Average patient age |
| Average dose |
| Number of new applications in 2017-2018 |
| Number of doctors |
| **Pricing** |
| Price per vial (GST ex) |
| Price per vial after 1 April 2019 |
| Annual average cost per patient for 2017-2018 |

Source: Australian Government Department of Health Life. Accessed 2019. Life Saving Drugs Program (LSDP) Attachment A (1) Brief overview of Fabry disease treated through the LSDP

A.4 PBAC submissions

All medicines on the LSDP have undergone assessment by the PBAC, but been rejected because of failure to meet the required cost-effectiveness criteria. These submissions will include both clinical effectiveness and safety clinical evaluation. The economic information, includes:

* type of economic evaluation
* comparator
* estimated number of patients with the disease
* estimated number of patients that will take the medicine

A.5 Specialist laboratory data

Diagnosis of Fabry disease is confirmed by measuring alpha-galactosidase A enzyme activity in the blood or by genetic testing for variants of the GLA gene. Fabry disease patient samples are delivered and processed at two national diagnostic labs:

(1) National Referral Laboratory, Department of Biochemical Genetics, Women's and Children's Hospital, SA

(2) Central Pathology Laboratory, Royal Brisbane and Women's Hospital, QLD

HealthConsult will be consulting with these two sites to retrieve de-identified diagnostic laboratory datasets that may be used to inform questions raised in the Review.

A.6 Rare disease registries

Rare disease registries are typically run by international pharmaceutical companies, such as Sanofi Genzyme, or Shire. These registries hold observational data for monitoring and evaluating patient outcomes in response to treatment specific to their condition. HealthConsult will be seeking access to Australian data held within de-identified patient registry databases to collect and analyse any information that may be relevant to the Review.

The databases of particular interest for the current Review include:

* Fabry Registry.

<https://www.registrynxt.com/>

* Fabry Outcome Survey (FOS).

<https://www.shiretrials.com/en/studies/clinicaltrialsen/2017/09/20/09/33/fos>

A.7 The Australia and New Zealand Dialysis and Transplant Registry

The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) collects and reports the incidence, prevalence and outcome of dialysis treatment and kidney transplantation for patients with end stage kidney disease across Australia and New Zealand. The Registry was established in 1977 from the merger of separate dialysis and transplant registries to provide information on the patterns and outcomes of dialysis and kidney transplantation, and to support safety and quality activities and the planning of appropriate health services.

A.8 Clinical Advisory Group

The Clinical Advisory Group (CAG) will be contacted by HealthConsult as required to provide expert advice and opinions on the LSDP reviews. This is likely to be required outside the requirement for data source: stakeholder consultations. However, CAG representatives will also likely be consulted for input into the reviews for the ToR including stakeholder consultations as CAG members are clinician experts in rare diseases.

A.9 Fabry Australia

Fabry Australia is a National Incorporated Association representing individuals and families diagnosed with Fabry disease from across Australia. Fabry Australia is committed to uniting the Australian Fabry community, by working together to improve the lives of those affected by Fabry disease. Fabry Australia established a Fabry clinic consisting of current Medical Advisors and Fabry Australia Committee members. The purpose of the Fabry Australia Medical Advisory Committee is:

* To promote and document ‘best practice’ of Fabry Disease Clinical Care. An impartial, sustainable model that practises co-ordinated, ongoing clinical care, including access to diagnostic testing, opportunities for ongoing research and access to safe, current treatments for Fabry Disease and a transitional program from paediatrics to adult care.
* To review the guidelines to access current Fabry Disease Treatments in Australia.
* To provide a forum for physicians and other professionals for collaboration, exploration and development of services for Fabry patients, their families and caregivers.
* To support Fabry Australia’s Fabry Patient Conference / meetings updating the Australian Fabry community of current research and clinical studies.

Fabry Australia input will be sought where data source “Stakeholder Consultation” is include in a ToR.

: Systematic literature review methodology

Systematic literature search

A systematic literature review is a rigorous and highly methodical appraisal and synthesis of research articles. 13 HealthConsult will conduct systematic reviews in three steps:

1. **Identification of relevant evidence** – The identification of evidence relevant to all ToR will rely on a systematic literature review. The search strategies will encompass both the peer-reviewed literature and any additional evidence (such as, published international registry data and public summary documents or unpublished PBAC pivotal trial data) provided by key stakeholders.

The Medline, EMBASE and Cochrane Library databases will be searched for eligible peer-reviewed articles. These will include clinical studies that consider the medicines agalsidase alfa (Replagal) and agalsidase beta (Fabrazyme) for the treatment of Fabry disease. Restrictions will be placed on the time period searched, from 2009 for ToR 1 (prevalence) and ToR 6 (utilisation) and 2012 for the rest of the ToR to capture evidence that has not previously been included/considered by the LSDP. The reference lists of relevant papers will also be scanned for other studies potentially missed in the database searches.

All eligible articles will be downloaded into EndNote (X 9). Two reviewers from the evidence review team will independently screen titles and abstracts (where available) for all citations retrieved by the literature search. All citations listed for inclusion for full text review will be independently assessed by the two independent reviewers. Any disagreements will be resolved by a third reviewer to reach consensus.

The ‘a priori’ inclusion criteria will be determined from the PICO criteria that form the basis of the research question. Studies reporting at least one primary outcome will be eligible for inclusion if they satisfied the correct population, intervention and comparator criteria. Outcomes of interest to be reported are relevant life extension, primary efficacy and safety outcomes (e.g. cholesterol, hearing test, respiratory function tests, urinalysis, cardiac, renal, cerebrovascular and pain outcomes). Exclusion criteria include literature identified as opinion pieces, editorials or other papers without a clear study design or description of methods or results or low powered statistical results. It also includes literature included in the 2015 LSDP review report.

Eligibility criteria will be applied to the titles and abstracts of included citations; full articles will be retrieved for further assessment where the citation appears to meet the eligibility criteria. The same criteria will be applied to the full articles. Full articles that initially met the eligibility criteria but which were later excluded will be documented, with reasons for exclusion reported. Study eligibility will be assessed by two reviewers from the evidence review team who will screen titles and abstracts (where available) for all citations retrieved by the literature search. All citations listed for inclusion for full text review will be assessed by the same independent reviewers. Any disagreements will be resolved by a third reviewer.

Studies will be assessed for eligibility for inclusion in the systematic review using a staged approach; that is, the highest level of evidence available to answer the individual research questions will be included in the systematic review. The level of evidence will be determined by the NHMRC Evidence Hierarchy for interventional evidence, as described in Appendix B.2. The use of a staged approach targets the research most likely to provide unbiased evidence as a consequence of how the research was designed. However, other factors, such as study quality, size of the treatment effect, generalisability and applicability of the evidence, will also be considered when assessing the reliability of study findings.

The flow of information through the different phases of the systematic literature review will be presented in a Preferred Reporting of Items in Systematic Reviews and Meta-analyses (PRISMA) flow diagram.13 Studies that initially met inclusion criteria but were later excluded will be documented, with reasons for their exclusion.

* 1. **Critical Appraisal of selected evidence** – Studies will be critically appraised according to the likelihood that bias had affected their findings. Study design flaws will be appraised using NHMRC levels of evidence (Appendix B.2).14 Systematic reviews will be critically appraised using the AMSTAR 2 (Assessing the Methodological Quality of Systematic Reviews) checklist (Appendix B.3). 15 The execution of RCTs and observational studies will be evaluated using quality appraisal checklists from Cochrane Risk of Bias for RCTs and ROBINS – 1 (Risk Of Bias In Non-randomised Studies - of Interventions) (see Appendix B.3). Case reports will not be assessed due to their likelihood of bias.

The quality of the body of evidence reported on individual health outcomes will be rated according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. 16 The GRADE system classifies the overall quality/level of the body of evidence for each outcome into one of four scores: 17

(1) **High:** we are very confident that the true effect lies close to that of the estimate of the effect.

(2) **Moderate:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

(3) **Low:** our confidence in the effect estimate is limited: the true effect maybe substantially different from the estimate of the effect.

(4) **Very low:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect.

Systematic reviews are considered to provide the strongest evidence if they summarise one or more well-designed and well-executed RCTs and yield consistent and directly applicable results. In the GRADE methodology, systematic reviews and RCTs both start as high-quality evidence. However, review authors can downgrade RCTs to moderate, low, or even very low quality evidence, depending on the presence of one or more of the following factors: limitations in the design and implementation of available studies suggesting high likelihood of bias; unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses); indirectness of evidence (indirect population, intervention, control, outcomes); imprecision of results (wide confidence intervals); and high probability of publication bias.

The moderate strength category is populated by RCTs with important limitations; observational studies are generally graded as low-quality evidence. If, however, these studies yield large effects and there is no obvious bias explaining those effects, reviewers may rate the evidence as moderate or – if the effect is large enough – even high quality.

(3) **Data extraction** – Relevant data will be extracted from included studies, including study design characteristics, country/setting, main population characteristics (including baseline characteristics or disease severity, if available), intervention drug and dosage details, comparator drug and dosage details, level of evidence, risk of bias, relevant outcome measures and results, and follow-up period. All data extraction will be cross-checked by a second reviewer.

Where appropriate, data extracted from the included studies will be combined in a meta-analysis, using Review Manager software from the Cochrane Collaboration. For each research question, the findings will be synthesised into an overall narrative, with better quality studies given greater weight in the formulation of conclusions. Where there is incomplete reporting of information in published systematic reviews, data will be verified using the original papers. The synthesis of the evidence will be informed by the GRADE method. 16

Levels of evidence

When identifying clinical evidence, a stepped process will generally be used in which the highest-level evidence will be assessed for inclusion before lower levels of evidence will be considered. If there is sufficient Level I evidence to address the ToR (and research questions), assessment of Level II, III and IV evidence will not be undertaken. If no relevant Level I evidence is available for a particular research question, Level II evidence will be assessed. If no relevant Level II evidence is available these steps will be repeated for lower levels of evidence. Table B-1 describes the NHMRC Levels of Evidence for intervention questions.

Table B-1: NHMRC evidence hierarchy for intervention questions

|  |  |  |
| --- | --- | --- |
| **Level** | **Study type** | **Notes** |
| I | A systematic review of level II studies | A systematic review will only be assigned a level of evidence as high as the studies it contains |
| II | A randomised controlled trial | - |
| III-1 | A pseudo-randomised controlled trial | - |
| III-2 | A comparative study with concurrent controls:* Non-randomised experimental trial
* Cohort study
* Case-control study
* Interrupted time series with a control group
 | Non-randomised experimental trial also includes controlled before-and-after (pre-test/post-test) studies, as well as indirect comparisons (i.e. utilise A v B and B v C to determine A v C) |
| III-3 | A comparative study without concurrent controls:* Historical control study
* Two or more single arm study
* Interrupted time series without a parallel control group
 | A comparison of single arm studies could involve case series from two studies. This would also include unadjusted indirect comparisons (utilise A v B and B v C to determine A v C, but where there is no statistical adjusted for B) |
| IV | Case series with either post-test or pre-test/post-test outcomes | - |

Source: National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for developers of guidelines. Canberra: National Health and Medical Research Council, 2009.

**Quality assessment**

Clinical treatment guidelines

Clinical treatment guidelines will be assessed using the AGREE II (Appraisal of Guidelines for Research and Evaluation II) checklist18 consisting of 23 items (See Table B-2). AGREE II allows for appraisers to make two final assessments of their overall judgement of the methodological quality of practice guidelines. This is made in consideration of how they rated the 23 items. Two appraisers will be used when evaluating the quality of outcomes.

The AGREE II guidelines are divided into six major quality domains:

1. Scope and purpose;
2. Stakeholder involvement;
3. Rigour of development;
4. Clarity of presentation;
5. Applicability; and
6. Editorial independence.

AGREE II items are rated out of 7, with a score of 1 being “Strongly Disagree,” and a score of 7 being “Strongly Agree.” A score between 2 and 6 is given when the AGREE II item does not fully meet the criteria or considerations. Scores are assigned based on completeness of data.

Table B-2: Quality assessment checklist for clinical guidelines

|  |  |  |
| --- | --- | --- |
| CHECKLIST ITEM AND DESCRIPTION | REPORTING CRITERIA | PAGE # |
| DOMAIN 1: SCOPE AND PURPOSE |
| 1. OBJECTIVESReport the overall objective(s) of the guideline. The expected health benefits from the guideline are to be specific to the clinical problem or health topic. | * + - Health intent(s) (i.e., prevention, screening, diagnosis, treatment, etc.)
* Expected benefit(s) or outcome(s)
* Target(s) (e.g., patient population, society)
 |  |
| 2. QUESTIONSReport the health question(s) covered by the guideline, particularly for the key recommendations. | * Target population
* Intervention(s) or exposure(s)
* Comparisons (if appropriate)
* Outcome(s)
* Health care setting or context
 |  |
| 3. POPULATIONDescribe the population (i.e., patients, public, etc.) to whom the guideline is meant to apply. | * Target population, sex and age
* Clinical condition (if relevant)
* Severity/stage of disease (if relevant)
* Comorbidities (if relevant)
* Excluded populations (if relevant)
 |  |
| DOMAIN 2: STAKEHOLDER INVOLVEMENT |
| 4. GROUP MEMBERSHIPReport all individuals who were involved in the development process. This may include members of the steering group, the research team involved in selecting and reviewing/rating the evidence and individuals involved in formulating the final recommendations. | * Name of participant
* Discipline/content expertise (e.g., neurosurgeon, methodologist)
* Institution (e.g., St. Peter’s hospital)
* Geographical location (e.g., Seattle, WA)
* A description of the member’s role in the guideline development group
 |  |
| 5. TARGET POPULATION PREFERENCES AND VIEWSReport how the views and preferences of the target population were sought/considered and what the resulting outcomes were. | * Statement of type of strategy used to capture patients’/publics’ views and preferences (e.g., participation in the guideline development group, literature review of values and preferences)
* Methods by which preferences and views were sought (e.g., evidence from literature, surveys, focus groups)
* Outcomes/information gathered on patient/public information
* How the information gathered was used to inform the guideline development process and/or formation of the recommendations
 |  |
| 6. TARGET USERSReport the target (or intended) users of the guideline. | * The intended guideline audience (e.g. specialists, family physicians, patients, clinical or institutional leaders/administrators)
* How the guideline may be used by its target audience (e.g., to inform clinical decisions, to inform policy, to inform standards of care)
 |  |
| DOMAIN 3: RIGOUR OF DEVELOPMENT |
| 7. SEARCH METHODSReport details of the strategy used to search for evidence. | * Named electronic database(s) or evidence source(s) where the search was performed (e.g., MEDLINE, EMBASE, PsychINFO, CINAHL)
* Time periods searched (e.g., January 1, 2004 to March 31, 2008)
* Search terms used (e.g., text words, indexing terms, subheadings)
* Full search strategy included (e.g., possibly located in appendix)
 |  |
| 8. EVIDENCE SELECTION CRITERIAReport the criteria used to select (i.e., include and exclude) the evidence. Provide rationale, where appropriate. | * Target population (patient, public, etc.) characteristics
* Study design
* Comparisons (if relevant)
* Outcomes
* Language (if relevant)
* Context (if relevant)
 |  |
| 9. STRENGTHS & LIMITATIONS OF THE EVIDENCEDescribe the strengths and limitations of the evidence. Consider from the perspective of the individual studies and the body of evidence aggregated across all the studies. Tools exist that can facilitate the reporting of this concept. | * Study design(s) included in body of evidence
* Study methodology limitations (sampling,
* blinding, allocation concealment, analytical
* methods)
* Appropriateness/relevance of primary and
* secondary outcomes considered
* Consistency of results across studies
* Direction of results across studies
* Magnitude of benefit versus magnitude of harm
* Applicability to practice context
 |  |
| 10. FORMULATION OF RECOMMENDATIONSDescribe the methods used to formulate the recommendations and how final decisions were reached. Specify any areas of disagreement and the methods used to resolve them. | * Recommendation development process (e.g., steps used in modified Delphi technique, voting procedures that were considered)
* Outcomes of the recommendation development process (e.g., extent to which consensus was reached using modified Delphi technique, outcome of voting procedures)
* How the process influenced the recommendations (e.g., results of Delphi technique influence final recommendation, alignment with recommendations and the final vote)
 |  |
| 11. CONSIDERATION OF BENEFITS AND HARMSReport the health benefits, side effects, and risks that were considered when formulating the recommendations. | * Supporting data and report of benefits
* Supporting data and report of harms/side effects/risks
* Reporting of the balance/trade-off between benefits and harms/side effects/risks
* Recommendations reflect considerations of both benefits and harms/side effects/risks
 |  |
| 12. LINK BETWEEN RECOMMENDATIONS AND EVIDENCEDescribe the explicit link between the recommendations and the evidence on which they are based. | * How the guideline development group linked and used the evidence to inform recommendations
* Link between each recommendation and key evidence (text description and/or reference list)
* Link between recommendations and evidence summaries and/or evidence tables in the results section of the guideline
 |  |
| 13. EXTERNAL REVIEWReport the methodology used to conduct the external review. | * Purpose and intent of the external review (e.g., to improve quality, gather feedback on draft recommendations, assess applicability and feasibility, disseminate evidence)
* Methods taken to undertake the external review (e.g., rating scale, open-ended questions)
* Description of the external reviewers (e.g., number, type of reviewers, affiliations)
* Outcomes/information gathered from the external review (e.g., summary of key findings)
* How the information gathered was used to inform the guideline development process and/or formation of the recommendations (e.g., guideline panel considered results of review in forming final recommendations)
 |  |
| 14. UPDATING PROCEDUREDescribe the procedure for updating the guideline. | * A statement that the guideline will be updated
* Explicit time interval or explicit criteria to guide decisions about when an update will occur
* Methodology for the updating procedure
 |  |
| DOMAIN 4: CLARITY OF PRESENTATION |
| 15. SPECIFIC AND UNAMBIGUOUS RECOMMENDATIONSDescribe which options are appropriate in which situations and in which population groups, as informed by the body of evidence. | * A statement of the recommended action
* Intent or purpose of the recommended action (e.g., to improve quality of life, to decrease side effects)
* Relevant population (e.g., patients, public)
* Caveats or qualifying statements, if relevant (e.g., patients or conditions for whom the recommendations would not apply)
* If there is uncertainty about the best care option(s), the uncertainty should be stated in the guideline
 |  |
| 16. MANAGEMENT OPTIONSDescribe the different options for managing the condition or health issue. | * Description of management options
* Population or clinical situation most appropriate to each option
 |  |
| 17. IDENTIFIABLE KEY RECOMMENDATIONSPresent the key recommendations so that they are easy to identify. | * Recommendations in a summarized box, typed in bold, underlined, or presented as flow charts or algorithms
* Specific recommendations grouped together in one section
 |  |
| DOMAIN 5: APPLICABILITY |
| **18. FACILITATORS AND BARRIERS TO APPLICATION** *Describe the facilitators and barriers to the guideline’s application.*  | * Types of facilitators and barriers that were considered
* Methods by which information regarding the facilitators and barriers to implementing recommendations were sought (e.g., feedback from key stakeholders, pilot testing of guidelines before widespread implementation)
* Information/description of the types of facilitators and barriers that emerged from the inquiry (e.g., practitioners have the skills to deliver the recommended care, sufficient equipment is not available to ensure all eligible members of the population receive mammography)
* How the information influenced the guideline development process and/or formation of the recommendations
 |  |
| **19. IMPLEMENTATION ADVICE/TOOLS** *Provide advice and/or tools on how the recommendations can be applied in practice.*  | * Additional materials to support the implementation of the guideline in practice. For example:
* Guideline summary documents
* Links to check lists, algorithms
* Links to how-to manuals
* Solutions linked to barrier analysis (see Item 18)
* Tools to capitalize on guideline facilitators (see Item 18)
* Outcome of pilot test and lessons learned
 |  |
| **20. RESOURCE IMPLICATIONS** *Describe any potential resource implications of applying the recommendations.*  | * Types of cost information that were considered (e.g., economic evaluations, drug acquisition costs)
* Methods by which the cost information was sought (e.g., a health economist was part of the guideline development panel, use of health technology assessments for specific drugs, etc.)
* Information/description of the cost information that emerged from the inquiry (e.g., specific drug acquisition costs per treatment course)
* How the information gathered was used to inform the guideline development process and/or formation of the recommendations
 |  |
| **21. MONITORING/ AUDITING CRITERIA** *Provide monitoring and/or auditing criteria to measure the application of guideline recommendations.*  | * Criteria to assess guideline implementation or adherence to recommendations
* Criteria for assessing impact of implementing the recommendations
* Advice on the frequency and interval of measurement
* Operational definitions of how the criteria should be measured
 |  |
| DOMAIN 6: EDITORIAL INDEPENDENCE |
| **22. FUNDING BODY** Report the funding body’s influence on the content of the guideline.  | * The name of the funding body or source of funding (or explicit statement of no funding)
* A statement that the funding body did not influence the content of the guideline
 |  |
| **23. COMPETING INTERESTS** Provide an explicit statement that all group members have declared whether they have any competing interests.  | * Types of competing interests considered
* Methods by which potential competing interests were sought
* A description of the competing interests
* How the competing interests influenced the guideline process and development of recommendations
 |  |

Source: Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L, for the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010;182:E839-842.

Systematic Reviews

Systematic reviews will be assessed using the AMSTAR 2 (Assessing the Methodological Quality of Systematic Reviews) checklist,15 which has 16 questions (see Table B-3). AMSTAR 2 enables appraisal of systematic reviews of randomised and non-randomised studies of healthcare interventions. AMSTAR 2 is not intended to generate an overall score. The overall rating is based on weaknesses in critical domains. The possible ratings of overall confidence in the results of the review are:

* **High** - Zero or one non-critical weakness: The systematic review provides an accurate and comprehensive summary of the results of the available studies that address the question of interest
* **Moderate** - More than one non-critical weakness\*: The systematic review has more than one weakness, but no critical flaws. It may provide an accurate summary of the results of the available studies that were included in the review.
* **Low** - One critical flaw with or without non-critical weaknesses: The review has a critical flaw and may not provide an accurate and comprehensive summary of the available studies that address the question(s) of interest.
* **Critically low** - More than one critical flaw with or without non-critical weaknesses: The review has more than one critical flaw and should not be relied on to provide an accurate and comprehensive summary of the available studies.

\*Note: Multiple non-critical weaknesses may diminish confidence in the review and it may be appropriate to move the overall appraisal down from moderate to low confidence.

Table B-3 presents the AMSTAR 2 tool, a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions.

Table B-3: Quality assessment checklist for systematic reviews

|  |
| --- |
| **AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both**  |
| **1. Did the research question and inclusion criteria for the review include the components of PICO?** |
| For Yes:[ ]  Population[ ]  Intervention[ ]  Comparator group[ ]  Outcome | Optional (recommended)[ ]  Timeframe for follow-up | [ ]  Yes[ ]  No |
| **2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol?** |
| For Partial Yes:The authors state that they had a written protocol or guide that included ALL the following:[ ]  review question(s)[ ]  a search strategy[ ]  inclusion/exclusion criteria[ ]  a risk of bias assessment | For Yes:As for partial yes, plus the protocol should be registered and should also have specified:[ ]  a meta-analysis/synthesis plan, if appropriate, *and*[ ]  a plan for investigating causes of heterogeneity[ ]  justification for any deviations from the protocol | [ ]  Yes[ ]  Partial Yes[ ]  No |
| **3. Did the review authors explain their selection of the study designs for inclusion in the review?** |
| For Yes, the review should satisfy ONE of the following:[ ]  *Explanation for* including only RCTs[ ]  OR *Explanation for* including only NRSI[ ]  OR *Explanation for* including both RCTs and NRSI |  | [ ]  Yes[ ]  No |
| **4. Did the review authors use a comprehensive literature search strategy?** |
| For Partial Yes (all the following):[ ]  searched at least 2 databases (relevant to research question)[ ]  provided key word and/or search strategy[ ]  justified publication restrictions (e.g. language) | For Yes, should also have (all the following):[ ]  searched the reference lists/bibliographies of included studies[ ]  searched trial/study registries[ ]  included/consulted content experts in the field[ ]  where relevant, searched for grey literature[ ]  conducted search within 24 months of completion of the review | [ ]  Yes[ ]  Partial Yes[ ]  No |
| **5. Did the review authors perform study selection in duplicate?** |
| For Yes, either ONE of the following:[ ]  at least two reviewers independently agreed on selection of eligible studies and achieved consensus on which studies to include[ ]  OR two reviewers selected a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder selected by one reviewer |  | [ ]  Yes[ ]  No |
| **6. Did the review authors perform data extraction in duplicate?** |
| For Yes, either ONE of the following:[ ]  at least two reviewers achieved consensus on which data to extract from included studies[ ]  OR two reviewers extracted data from a sample of eligible studies and achieved good agreement (at least 80 percent), with the remainder extracted by one reviewer |  | [ ]  Yes[ ]  No |
| **7. Did the review authors provide a list of excluded studies and justify the exclusions?** |
| For Partial Yes:[ ]  provided a list of all potentially relevant studies that were read in full-text form but excluded from the review | For Yes, must also have:[ ]  justified the exclusion from the review of each potentially relevant study | [ ]  Yes[ ]  Partial Yes[ ]  No |
| **8. Did the review authors describe the included studies in adequate detail?** |
| For Partial Yes (ALL the following):[ ]  described population[ ]  described interventions[ ]  described comparators[ ]  described outcomes[ ]  described research designs | For Yes, should also have ALL the following:[ ]  described population in detail[ ]  described interventions in detail (including doses where relevant)[ ]  described comparators in detail (including doses where relevant)[ ]  described study’s setting[ ]  timeframe for follow-up | [ ]  Yes[ ]  Partial Yes[ ]  No |
| **9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review?** |
| **RCTs**For Partial Yes, must have assessed RoB from:[ ]  unconcealed allocation, *and*[ ]  lack of blinding of patients and assessors when assessing outcomes (unnecessary for objective outcomes such as all-cause mortality) | For Yes, must also have assessed RoB from:[ ]  allocation sequence that was not truly random, *and*[ ]  selection of the reported result from among multiple measurements or analyses of a specified outcome | [ ]  Yes[ ]  Partial Yes[ ]  No[ ]  Includes only NRSI |
| **NRSI**For Partial Yes, must have assessed RoB:[ ]  from confounding, *and*[ ]  from selection bias | For Yes, must also have assessed RoB:[ ]  methods used to ascertain exposures and outcomes, *and*[ ]  selection of the reported result from among multiple measurements or analyses of a specified outcome | [ ]  Yes[ ]  Partial Yes[ ]  No[ ]  Includes only RCTs |
| **10. Did the review authors report on the sources of funding for the studies included in the review?** |
| For Yes:[ ]  must have reported on the sources of funding for individual studies included in the review. Note: reporting that the reviewers looked for this information but it was not reported by study authors also qualifies |  | [ ]  Yes[ ]  No |
| **11. If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results?** |
| **RCTs**For Yes:[ ]  the authors justified combining the data in a meta-analysis[ ]  AND they used an appropriate weighted technique to combine study results and adjusted for heterogeneity if present[ ]  AND investigated the causes of any heterogeneity |  | [ ]  Yes[ ]  No[ ]  No meta-analysis conducted |
| **For NRSI**For Yes:[ ]  the authors justified combining the data in a meta-analysis[ ]  AND they used an appropriate weighted technique to combine study results, adjusting for heterogeneity if present[ ]  AND they statistically combined effect estimates from NRSI that were adjusted for confounding, rather than combining raw data, or justified combining raw data when adjusted effect estimates were not available[ ]  AND they reported separate summary estimates for RCTs and NRSI separately when both were included in the review |  | [ ]  Yes[ ]  No[ ]  No meta-analysis conducted |
| **12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis?** |
| For Yes:[ ]  included only low risk of bias RCTs[ ]  OR, if the pooled estimate was based on RCTs and/or NRSI at variable RoB, the authors performed analyses to investigate possible impact of RoB on summary estimates of effect |  | [ ]  Yes[ ]  No[ ]  No meta-analysis conducted |
| **13. Did the review authors account for RoB in individual studies when interpreting/discussing the results of the review?** |
| For Yes:[ ]  included only low risk of bias RCTs[ ]  OR, if RCTs with moderate or high RoB, or NRSI were included the review provided a discussion of the likely impact of RoB on the results |  | [ ]  Yes[ ]  No |
| **14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review?** |
| For Yes:[ ]  There was no significant heterogeneity in the results[ ]  OR if heterogeneity was present, the authors performed an investigation of sources of any heterogeneity in the results and discussed the impact of this on the results of the review |  | [ ]  Yes[ ]  No |
| **15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?** |
| For Yes:[ ]  performed graphical or statistical tests for publication bias and discussed the likelihood and magnitude of impact of publication bias |  | [ ]  Yes[ ]  No[ ]  No meta-analysis conducted |
| **16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?** |
| For Yes:[ ]  The authors reported no competing interests OR[ ]  The authors described their funding sources and how they managed potential conflicts of interest |  | [ ]  Yes[ ]  No |

Source: Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017 Sep 21;358:j4008.

Randomised Controlled Trials (RCTs)

Quality appraisal checklists from the Revised Cochrane risk-of-bias tool for randomised trials (RoB 2)19 will be used to assess the quality of RCTs (Table B-4). The RoB 2 tool provides a framework for considering the risk of bias in the findings of any type of randomized trial. The assessment is specific to a single trial result that is an estimate of the relative effect of two interventions or intervention strategies on a particular outcome. We refer to the interventions as the experimental intervention and the comparator intervention, although we recognise that the result may sometimes refer to a comparison of two active interventions.

The RoB2 tool is structured into five domains through which bias might be introduced into the result. These are:

1. bias arising from the randomisation process;
	1. bias due to deviations from intended interventions;
	2. bias due to missing outcome data;
	3. bias in measurement of the outcome;
	4. bias in selection of the reported result.

The domain names are direct descriptions of the causes of bias addressed in the domain.

|  |
| --- |
| Table B-4: Quality assessment checklist for randomised controlled trials (Cochrane RoB 2) |
| **Domain 1: Risk of bias arising from the randomization process** |
| **Signalling Questions** | **Description** | **Response options** |
| 1.1 Was the allocation sequence random? |  | Y / PY / PN / N / NI |
| 1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions? | Y / PY / PN / N / NI |
| 1.3 Did baseline differences between intervention groups suggest a problem with the randomization process? |  | Y / PY / PN / N / NI |
| Risk-of-bias judgement |  | Low / High / Some concerns |
| Optional: What is the predicted direction of bias arising from the randomization process? |  | Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable |
| **Domain 2: Risk of bias due to deviations from the intended interventions (effect of assignment to intervention)** |
| **Signalling questions** | **Description** | **Response options** |
| 2.1. Were participants aware of their assigned intervention during the trial? |  | Y / PY / PN / N / NI |
| 2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? | Y / PY / PN / N / NI |
| 2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context? |  | NA / Y / PY / PN / N / NI |
| 2.4. If Y/PY to 2.3: Were these deviations from intended intervention balanced between groups? |  |  NA / Y / PY / PN / N / NI |
| 2.5 If N/PN/NI to 2.4: Were these deviations likely to have affected the outcome? |  | NA / Y / PY / PN / N / NI |
| 2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention? |  | Y / PY / PN / N / NI |
| 2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized? |  | NA / Y / PY / PN / N / NI |
| Risk-of-bias judgement |  | Low / High / Some concerns |
| Optional: What is the predicted direction of bias due to deviations from intended interventions? |  | Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable |
| **Domain 2: Risk of bias due to deviations from the intended interventions (effect of adhering to intervention)** |
| **Signalling questions** | **Description** | **Response options** |
| 2.1. Were participants aware of their assigned intervention during the trial? |  | Y / PY / PN / N / NI |
| 2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial? |  | Y / PY / PN / N / NI |
| 2.3. If Y/PY/NI to 2.1 or 2.2: Were important co-interventions balanced across intervention groups? |  | NA / Y / PY / PN / N / NI |
| 2.4. Could failures in implementing the intervention have affected the outcome? |  | Y / PY / PN / N / NI |
| 2.5. Did study participants adhere to the assigned intervention regimen? |  | Y / PY / PN / N / NI |
| 2.6. If N/PN/NI to 2.3 or 2.5 or Y/PY/NI to 2.4: Was an appropriate analysis used to estimate the effect of adhering to the intervention? |  | NA / Y / PY / PN / N / NI |
| Risk-of-bias judgement |  | Low / High / Some concerns |
| Optional: What is the predicted direction of bias due to deviations from intended interventions? |  | Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable |
| **Domain 3: Missing outcome data** |
| **Signalling questions** | **Description** | **Response options** |
| 3.1 Were data for this outcome available for all, or nearly all, participants randomized? |   | Y / PY / PN / N / NI |
| 3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data? |  | NA / Y / PY / PN / N |
| 3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? |  | NA / Y / PY / PN / N / NI |
| 3.4 If Y/PY/NI to 3.3: Do the proportions of missing outcome data differ between intervention groups?  |  | NA / Y / PY / PN / N / NI |
| 3.5 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value? |  | NA / Y / PY / PN / N / NI |
| Risk-of-bias judgement |  | Low / High / Some concerns |
| Optional: What is the predicted direction of bias due to missing outcome data? |  | Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable |
| **Domain 4: Risk of bias in measurement of the outcome** |
| **Signalling questions** | **Description** | **Response options** |
| 4.1 Was the method of measuring the outcome inappropriate? |  | Y / PY / PN / N / NI |
| 4.2 Could measurement or ascertainment of the outcome have differed between intervention groups? |  | Y / PY / PN / N / NI |
| 4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants? |  | Y / PY / PN / N / NI |
| 4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received? |  | NA / Y / PY / PN / N / NI |
| 4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received? |  | NA / Y / PY / PN / N / NI |
| Risk-of-bias judgement |  | Low / High / Some concerns |
| Optional: What is the predicted direction of bias in measurement of the outcome? |  | Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable |
| **Domain 5: Risk of bias in selection of the reported result** |
| **Signalling questions** | **Description** | **Response options** |
| 5.1 Was the trial analysed in accordance with a pre-specified plan that was finalized before unblinded outcome data were available for analysis? |  | Y / PY / PN / N / NI |
| Is the numerical result being assessed likely to have been selected, on the basis of the results, from... |  |  |
| 5.2. ... multiple outcome measurements (e.g. scales, definitions, time points) within the outcome domain? |  | Y / PY / PN / N / NI |
| 5.3 ... multiple analyses of the data? |  | Y / PY / PN / N / NI |
| Risk-of-bias judgement |  | Low / High / Some concerns |
| Optional: What is the predicted direction of bias due to selection of the reported result? |  | Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable |
| **Overall risk of bias** |
| **Risk-of-bias judgement** |  | **Low / High / Some concerns** |
| **Optional: What is the predicted direction of bias due to selection of the reported result?** |  | **Favours experimental / Favours comparator / Towards null /Away from null / Unpredictable** |

Source: Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Edited by Julian PT Higgins, Jelena Savović, Matthew J Page, Jonathan AC Sterne on behalf of the ROB2 Development Group. Accessed 9 October 2018 https://sites.google.com/site/riskofbiastool/

Abbreviations: Y, Yes; PY, Probably yes; PN, Probably no; N, No; NI, No information

Notes: Responses underlined in green are potential markers for low risk of bias, and responses in red are potential markers for a risk of bias. Where questions relate only to sign posts to other questions, no formatting is used.

The response options for an overall risk-of-bias judgement are the same as for individual domains. Reaching an overall risk-of-bias judgement for a specific outcome is presented in Table B-5 below.

Table B-5: Quality assessment checklist for randomised controlled trials (RoB 2)

|  |
| --- |
| **Reaching an overall risk-of-bias judgement for a specific outcome.** |
| **Overall risk-of-bias judgement** | **Criteria** |
| Low risk of bias | The study is judged to be at **low risk of bias** for all domains for this result. |
| Some concerns | The study is judged to raise **some concerns** in at least one domain for this result, but not to be at high risk of bias for any domain. |
| High risk of bias | The study is judged to be at **high risk of bias** in at least one domain for this result.OrThe study is judged to have **some concerns** for **multiple domains** in a way that substantially lowers confidence in the result. |

Source: Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Edited by Julian PT Higgins, Jelena Savović, Matthew J Page, Jonathan AC Sterne on behalf of the ROB2 Development Group. 9 October 2018 https://sites.google.com/site/riskofbiastool/

Non-randomised trials

The ROBINS-I tool (“Risk of Bias in Non-randomized Studies - of Interventions”) is concerned with evaluating the risk of bias in the results of nonrandomized studies of the effects of interventions (NRSIs) that compare the health effects of two or more interventions (Table B-6). The types of NRSIs that can be evaluated using this tool are quantitative studies estimating the effectiveness (harm or benefit) of an intervention, which did not use randomization to allocate units (individuals or clusters of individuals) to comparison groups. This includes studies where allocation occurs during the course of usual treatment decisions or peoples’ choices: such studies are often called “observational”. There are many types of such NRSIs, including cohort studies, case-control studies, controlled before-and-after studies, interrupted time-series studies and controlled trials in which intervention groups are allocated using a method that falls short of full randomization (sometimes called “quasi-randomized” studies).

Table B-6: Quality assessment checklist for cohort studies (ROBINS -1)

|  |  |  |
| --- | --- | --- |
| **Bias domain** | **Signalling questions** | **Response options** |
| **Bias due to confounding** |
|  | 1.1 Is there potential for confounding of the effect of intervention in this study?If N/PN to 1.1: the study can be considered to be at low risk of bias due to confounding and no further signalling questions need be considered | Y / PY / PN / N |
|  | If Y/PY to 1.1: determine whether there is a need to assess time-varying confounding: |  |
|  | 1.2. Was the analysis based on splitting participants’ follow up time according to intervention received?If N/PN, answer questions relating to baseline confounding (1.4 to 1.6) If Y/PY, go to question 1.3. | NA / Y / PY / PN / N /NI |
|  | 1.3. Were intervention discontinuations or switches likely to be related to factors that are prognostic for the outcome?If N/PN, answer questions relating to baseline confounding (1.4 to 1.6) If Y/PY, answer questions relating to both baseline and time-varying confounding (1.7 and 1.8) | NA / Y / PY / PN / N /NI |
| Questions relating to baseline confounding only |
|  | 1.4. Did the authors use an appropriate analysis method that controlled for all the important confounding domains? | NA / Y / PY / PN / N /NI |
|  | 1.5. If Y/PY to 1.4: Were confounding domains that were controlled for measured validly and reliably by the variables available in this study? | NA / Y / PY / PN / N /NI |
|  | 1.6. Did the authors control for any post- intervention variables that could have been affected by the intervention? | NA / Y / PY / PN / N /NI |
| Questions relating to baseline and time-varying confounding |
|  | 1.7. Did the authors use an appropriate analysis method that controlled for all the important confounding domains and for time-varying confounding? | NA / Y / PY / PN / N /NI |
|  | 1.8. If Y/PY to 1.7: Were confounding domains that were controlled for measured validly and reliably by the variables available in this study? | NA / Y / PY / PN / N /NI |
|  | Risk of bias judgement | Low / Moderate /Serious / Critical / NI |
|  | Optional: What is the predicted direction of bias due to confounding? | Favoursexperimental /Favours comparator/ Unpredictable |
| **Bias in selection of participants into the study** |
|  | 2.1. Was selection of participants into the study (or into the analysis) based on participant characteristics observed after the start of Intervention?If N/PN to 2.1: go to 2.4 2.2. If Y/PY to 2.1: Were the post- intervention variables that influenced selection likely to be associated withintervention?2.3 If Y/PY to 2.2: Were the post intervention variables that influenced selection likely to be influenced by the outcome or a cause of the outcome? | Y / PY / PN / N / NINA / Y / PY / PN / N /NINA / Y / PY / PN / N /NI |
|  | 2.4. Do start of follow-up and start of intervention coincide for mostparticipants? | Y / PY / PN / N / NI |
|  | 2.5. If Y/PY to 2.2 and 2.3, or N/PN to2.4: Were adjustment techniques used that are likely to correct for the presence of selection biases? | NA / Y / PY / PN / N /NI |
|  | Risk of bias judgement | Low / Moderate /Serious / Critical / NI |
|  | Optional: What is the predicted direction of bias due to selection of participants into the study? | Favoursexperimental /Favours comparator/ Towards null /Awayfrom null /Unpredictable |
| **Bias in classification of interventions** |
|  | 3.1 Were intervention groups clearly defined? | Y / PY / PN / N / NI |
|  | 3.2 Was the information used to define intervention groups recorded at the start of the intervention? | Y / PY / PN / N / NI |
|  | 3.3 Could classification of intervention status have been affected by knowledge of the outcome or risk of the outcome? | Y / PY / PN / N / NI |
|  | Risk of bias judgement | Low / Moderate /Serious / Critical / NI |
|  | Optional: What is the predicted direction of bias due to measurement of outcomes or interventions? | Favours experimental /Favours comparator / Towards null /Away from null /Unpredictable |
| **Bias due to deviations from intended interventions** |
|  | If your aim for this study is to assess the effect of assignment to intervention, answer questions 4.1 and 4.2 |  |
|  | 4.1. Were there deviations from the intended intervention beyond what would be expected in usual practice? | Y / PY / PN / N / NI |
|  | 4.2. If Y/PY to 4.1: Were these deviations from intended intervention unbalanced between groups and likely to have affected the outcome? | NA / Y / PY / PN / N /NI |
|  | If your aim for this study is to assess the effect of starting and adhering to intervention, answer questions 4.3 to 4.6 |  |
|  | 4.3. Were important co-interventions balanced across intervention groups? | Y / PY / PN / N / NI |
|  | 4.4. Was the intervention implemented successfully for most participants? | Y / PY / PN / N / NI |
|  | 4.5. Did study participants adhere to the assigned intervention regimen? | Y / PY / PN / N / NI |
|  | 4.6. If N/PN to 4.3, 4.4 or 4.5: Was an appropriate analysis used to estimate the effect of starting and adhering to the intervention? | NA / Y / PY / PN / N /NI |
|  | Risk of bias judgement |  |
|  | Optional: What is the predicted direction of bias due to deviations from the intended interventions? |  |
| **Bias due to missing data** |
|  | 5.1 Were outcome data available for all, or nearly all, participants? | Y / PY / PN / N / NI |
|  | 5.2 Were participants excluded due to missing data on intervention status? | Y / PY / PN / N / NI |
|  | 5.3 Were participants excluded due to missing data on other variables needed for the analysis? | Y / PY / PN / N / NI |
|  | 5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3:Are the proportion of participants and reasons for missing data similar across interventions? | NA / Y / PY / PN / N /NI |
|  | 5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Isthere evidence that results were robust to the presence of missing data? | NA / Y / PY / PN / N /NI |
|  | Risk of bias judgement | Low / Moderate /Serious / Critical / NI |
|  | Optional: What is the predicted direction of bias due to missing data? | Favoursexperimental /Favours comparator/ Towards null /Awayfrom null /Unpredictable |
| **Bias in measurement of outcomes** |
|  | 6.1 Could the outcome measure have been influenced by knowledge of the intervention received? | Y / PY / PN / N / NI |
|  | 6.2 Were outcome assessors aware of the intervention received by study participants? | Y / PY / PN / N / NI |
|  | 6.3 Were the methods of outcome assessment comparable acrossintervention groups? | Y / PY / PN / N / NI |
|  | 6.4 Were any systematic errors in measurement of the outcome related to intervention received? | Y / PY / PN / N / NI |
|  | Risk of bias judgement | Low / Moderate / Serious / Critical / NI |
|  | Optional: What is the predicted direction of bias due to measurement of outcomes? | Favours experimental /Favours comparator / Towards null /Away from null /Unpredictable |
| **Bias in selection of the reported result** |
|  | Is the reported effect estimate likely to be selected, on the basis of the results, from...7.1. ... multiple outcome *measurements* within the outcome domain? | Y / PY / PN / N / NI |
|  | 7.2 ... multiple *analyses* of the intervention-outcome relationship? | Y / PY / PN / N / NI |
|  | 7.3 ... different *subgroups?* | Y / PY / PN / N / NI |
|  | Risk of bias judgement | Low / Moderate /Serious / Critical / NI |
|  | Optional: What is the predicted direction of bias due to selection of the reported result? | Favours experimental /Favours comparator / Towards null /Away from null / Unpredictable |
| **Overall bias** |
|  | Risk of bias judgement | Low / Moderate /Serious / Critical / NI |
|  | Optional: What is the overall predicted direction of bias for this outcome? | Favoursexperimental /Favours comparator/ Towards null /Awayfrom null /Unpredictable |

Source: Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JPT. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ 2016; 355; i4919; doi: 10.1136/bmj.i4919.

Abbreviations: Y, Yes; PY, Probably yes; PN, Probably no; N, No; NI, No information

Notes: Responses underlined in green are potential markers for low risk of bias, and responses in red are potential markers for a risk of bias. Where questions relate only to sign posts to other questions, no formatting is used.

Prisma flow diagram

The flow of information through the different phases of the systematic literature review will be presented in a PRISMA Flow Diagram. Figure B-1 presents a PRISMA flow chart for systematic review.

Figure B-1: PRISMA flow chart for systematic review



Source: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and MetaAnalyses: The PRISMA Statement. PLoS Med 6(7)

: Fabry disease in Australia

This Appendix provides a brief description of Fabry disease and how it is diagnosed and managed.

**Description and diagnosis of Fabry disease**

Fabry disease is a rare disease caused by deleterious mutations[[1]](#footnote-2) in the *GLA* gene. This leads to a loss of enzyme activity in alpha-galactosidase A, which is otherwise important for breaking down glycosphingolipid waste products such as globotriaosylcermide and galactosylceramide in cells.20, 21 Deficiency in the alpha-galactosidase A results in progressive lysosomal accumulation of glycosphingolipid deposits, which in turn leads to cell damage in multiple tissues and organs of the body. The organs most affected include the kidneys, heart, nervous system, eyes, gastrointestinal tract and skin.

The disease is pan-ethnic and can be inherited via X-chromosome linkage. Early signs of the disease are observed in paediatric patients, and include chronic pain, abnormal sweating, nausea, abdominal pain, diarrhoea, and stunted growth. Affected males display the ‘classic’ severe phenotype, including early-onset of symptoms such as periodic crises of extreme pain and burning sensations, appearance of skin lesions, and corneal opacities. As Fabry disease patients age, there is progressive involvement of the kidneys, heart, and cerebrovascular disease leading to end-stage renal failure, cardiomyopathy, ischaemia and strokes in adults. These represent the major causes of disease-related morbidity.21 Symptoms in heterozygous *GLA* females can greatly vary, from being asymptomatic or mild to late-onset multi-organ involvement.

In Australia, Fabry disease patients are clinically diagnosed by analysing alpha-galactosidase A activity in a blood test, where no detection or low levels of enzyme activity in leukocytes with or without raised globotriaosylceramide plasma concentration, is an indicator of disease.22, 23 The ‘classic’ form of Fabry disease occurs in males with less than 1% alpha-galactosidase A activity. Genetic screening is also used to identify *GLA* mutations in heterozygous females showing normal levels of enzyme in their blood. The enzyme assay and genetic test are consistent with the eligibility criteria for Australian Fabry disease patients seeking access to LSDP medicines.

**Access to LSDP medicines for patients with Fabry disease**

The LSDP subsidises the full cost of two medications used to treat patients with Fabry disease. Patients need to satisfy the criteria set out in Table C-1 to be eligible for LSDP subsidies.

Table C-1: LSDP Guidelines on patient eligibility criteria

|  |  |  |  |
| --- | --- | --- | --- |
| **Overarching criteria for all patients** | **Criteria for initial application** | **Criteria for ongoing treatment** | **Exclusion criteria** |
| * Patient is permanent Australian resident who qualifies for Medicare.
* Patient is not suffering from any other medical condition, including complications or sequelae of the primary condition that might compromise the effectiveness of the LSDP drug under application.
* Patient meets the initial and ongoing criteria outlined in LSDP Guidelines (detailed below) for individual disease-specific medicines listed on the LSDP.
* Patient must participate in the evaluation of effectiveness of the drug by periodic assessment, as directed by the LSDP Guidelines, or have a reason not to participate.
 | 1. **Diagnosis of Fabry disease:** Deficiency of alpha-galactosidase enzyme activity in blood or white cells or by the presence of genetic mutations resulting in deficiency of alpha-galactosidase enzyme activity.

**plus ONE of the points (b) to (e) below**1. **Confirmation of Fabry-related renal disease by renal biopsy:** The biopsy is to demonstrate focal glomerular sclerosis or fibrosis linked to Fabry disease and exclude other causes of nephropathy.

In male Fabry disease patients:* abnormal albumin (> 20µg/min), as determined by 2 separate samples, at least 24 hours apart; and/or
* abnormal protein excretion (>150mg/24 hours); and/or
* albumin: creatinine ratio greater than upper limit of normal, in 2 separate samples, at least 24 hours apart; and/or
* renal disease due to long-term accumulation of glycosphingolipids in the kidneys.

In female patients:* proteinuria >300mg/24 hours with clinical evidence of progression.
* renal disease due to long-term accumulation of glycosphingolipids in the kidneys.
1. **Fabry-related cardiac disease:** Confirmation by myocardial biopsy is recommended to exclude other causes of cardiac hypertrophy.
* left ventricular hypertrophy, as evidenced by cardiac MRI or echocardiogram data, in the absence of hypertension. If hypertension is present, it should be treated optimally for at least 6 months prior to LSDP application through this criterion.
* significant life-threatening arrhythmia or conduction defect.
1. **Ischaemic vascular disease:** Shown on objective testing with no other cause or risk factors identified.
2. **Uncontrolled chronic pain:** Chronic pain despite the use of maximum doses of appropriate analgesia and antiepileptic medications for peripheral neuropathy. Patients meeting this criterion must provide ongoing evidence of effect, through analgesic intake, pain diary, summary letter from treating physician.
 | Subsidised treatment may continue unless one or more of the following situations apply:* failure to comply adequately with treatment or measures
* failure to provide data, copies of the test results and the Excel spreadsheet for Fabry disease, evidencing the effectiveness of the therapy
* therapy fails to relieve the symptoms of disease that originally resulted in the patient being approved for subsidised treatment
* the patient has severe infusion-related adverse reactions which are not preventable by appropriate pre-medication and/or adjustment of infusion rates and has a non-amenable mutation to migalastat
* the patient develops another life threatening or severe disease where the long-term prognosis is unlikely to be influenced by LSDP subsidised treatment
* the patient develops another medical condition that might reasonably be expected to compromise a response to LSDP subsidised treatment
* presentation of conditions listed in the exclusion criteria.
 | The following conditions render a patient **ineligible** of subsidised treatment of Fabry disease through the LSDP:* Patients with related Fabry disease conditions which may compromise response to ERT.
* Patients with a presence of another life threatening or severe disease where the long-term prognosis is unlikely to be influenced by ERT.
* The presence of another medical condition that might reasonably be expected to compromise a response to ERT or migalastat.
* Patients participating in an active clinical trial are not eligible for subsidised treatment through the LSDP.
 |

Source: Australian Government. Department of Health (2018) *Life Saving Drugs Program - Information for patients, prescribers and pharmacists*.24 ; Australian Government. Department of Health (2018) *Life Saving Drugs Program (LSDP) guidelines for initial application and annual reapplication for subsidised treatment for Fabry disease*.7

The LSDP guidelines currently require a diagnosis of Fabry disease to be detected by a deficiency of alpha-galactosidase enzyme activity in blood or white cells or by the presence of genetic mutations resulting in deficiency of alpha-galactosidase enzyme activity. This diagnosis must be accompanied with either/or confirmation of:

* Fabry-related renal disease by renal biopsy
* Fabry-related cardiac disease by myocardial biopsy
* Ischaemic vascular disease
* Uncontrolled chronic pain.

Figure C.1 provides a simplified clinical treatment algorithm of how patients diagnosed with Fabry disease obtain access to treatment on the LSDP. More information on how the current guidelines determine access to Fabry disease medication can be found in Table C-1 of Appendix C.2. Testing protocols and clinical results that are monitored as part of the LSDP can be found in Table A-1 of Appendix A.

FigureC.1: Clinical treatment algorithm for Fabry Disease patients



Source: Laney et al., 2013 Figure 1 p55925; Sirrs et al., 2017 Figure 1 p1126; TGA 201727; TGA 201828, 29

Abbreviations GLA, alpha-galactosidase A; LSDP, Life Savings Drugs Program; PO, taken by mouth; q2w, every 2 weeks

Notes: Access to Migalastat is subject to presentation of amenable GLA mutations29. A full list of the GLA amenable mutations can be found in the Migalastat PI30 LSDP eligibility criteria provided in greater detail in Table C-1 of Appendix C.2

**Pharmacological management of Fabry disease**

In Australia, ERT is the primary approach to stabilising Fabry disease. On 1st November 2018, the Department has however listed a pharmacological chaperone therapy, migalastat (Galafold)31 on the LSDP for treatment of Fabry disease. This new oral medication is outside the scope of this review and was approved by the Therapeutic Goods Administration (TGA) on August, 2017.32

There are currently two ERT biopharmaceuticals used for long-term treatment of Fabry disease through the LSDP. These were made available on the LSDP in 2004 and include agalsidase alfa (Replagal) and agalsidase beta (Fabrazyme).

* **Replagal** – human alpha-galactosidase A produced by *in vitro* overexpression in the HT-1080 human cell line. The drug is administered in adults and children 6.5 years of age or older by intravenous infusion at 0.2 mg/kg body weight over a period of 40 minutes once every two weeks.33 Replagal is not recommended for children below 6.5 years old.
* **Fabrazyme** – manufactured from recombinant DNA technology in the hamster CHO cell line. Fabry disease patients are intravenously infused with the drug at 1 mg/kg body weight at a maximum rate of 0.25 mg/min once every two weeks.34 Fabrazyme is used in adults and children aged 8 years and over. Fabry disease patients younger than 8 years of age may be treated with Fabrazyme when clearly needed and after a careful risk/benefit analysis has been conducted by the physician.35

Medications for symptom management are also considered alongside ERT, especially in patients with organ dysfunction.36 For instance, Fabry disease patients with renal failure may require management of anaemia, bone disease and hypertension. To treat cardiovascular manifestations of Fabry disease, common heart disease drug interventions include diuretics, angiotension-converting enzyme (ACE) inhibitors, or angiotensin II receptor blockers (ARBs). For Fabry disease patients at high risk of cerebrovascular complications, prophylactic measures such as aspirin may be considered. Chronic pain associated with Fabry disease can be managed with analgesics. In addition, phenytoin, carbamazepine, gabapentin, tricyclic antidepressants and topiramate are also used to manage pain symptoms in Fabry disease.

Table C-2 summarises the two LSDP-funded medicines used for Fabry disease management including units/vial, date of listing and sponsor.

Table C-2: LSDP-subsidised ERT for the treatment of Fabry disease

|  |  |  |  |
| --- | --- | --- | --- |
| **Medicine** | **mg / vial** | **Date of listing** | **Sponsor** |
| Agalsidase alfa (Replagal®) | 3.5 | 1/07/2004 | Shire |
| Agalsidase beta (Fabrazyme®) | 5 | 1/07/2004 | Genzyme |
| 35 |

: Potential Search Terms

Potential Search terms: Tor 1

ToR 1 involves a systematic review of peer-reviewed papers and grey literature. As part of the systematic review, various data sources and databases will be examined to search for relevant evidence. The following search terms will be used for the systematic review in ToR 1:

(“Fabry disease” OR “Anderson-Fabry” OR “Fabry” OR "angiokeratoma corporis diffusum" OR "Hereditary dystopic lipidosis" OR "Alpha-galactosidase A deficiency" OR "GLA deficiency" OR “GLA mutation” OR “GLA polymorphism” OR "Ceramide trihexosidase deficiency") AND (Prevalence OR Epidemiology OR Incidence OR Morbidity OR “Allele frequency” OR “Mutation frequency” OR Cases OR Mortality OR Deaths OR Survival)

Potential search terms: ToR 2

CADTH’s database of search filters11 were consulted for this ToR. Below is the PubMed search string used for this ToR:

“Fabry” OR “Anderson-Fabry” OR "angiokeratoma corporis diffusum" OR "Hereditary dystopic lipidosis" OR "Alpha-galactosidase A deficiency" OR "GLA deficiency" OR "Ceramide trihexosidase deficiency") AND (Patient OR Paediatric) AND (Clinical pathway OR Clinical protocol OR Consensus OR Consensus development conferences as topic OR Critical pathways OR Guidelines as topic [Mesh:NoExp] OR Practice guidelines as topic OR Health planning guidelines OR guideline OR practice guideline OR consensus development conference OR consensus development conference OR position statement\* OR policy statement\* OR practice parameter\* OR best practice\* OR standards OR guideline\* OR clinical algorithm\* OR recommendat\* OR screening OR examination OR assessment\* OR test\*) AND (Monitoring OR Outcomes OR “Follow up” OR “Disease severity”

Potential search terms: ToR 3

A comprehensive search of the scientific literature will be conducted to identify randomised controlled trials addressing the key research questions. Potential search terms for the identification of evidence relating to **ToR 3**, agalsidase alfa and agalsidase beta to placebo and against each other within the database MEDLINE (via PUBMED.com) are shown in Table D-1. Syntax will be modified for database searches in EMBASE (via EMBASE.com), Cochrane Library (Includes the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials and the Health Technology Assessment database), ClinicalTrials.gov, International Clinical Trials Registry Platform, Australian Clinical Trials Registry, Internal registries (e.g., Original PBAC funding application pivotal trials that informed the medicines inclusion on the LSDP) and other sources (e.g., Database of Adverse Events Notifications Data from ARTG, PBAC PSDs for Fabry disease, Product information documents for Fabry disease medicines on the ARTG, AIHW National Death Index data and Cause of Death data, Fabry disease registry and Fabry Outcome Study published registry data reports).

Table D-1: Search terms for Medline (via PubMed) ToR 3, agalsidase alfa and agalsidase beta to placebo and against each other. ≠

|  |  |  |
| --- | --- | --- |
| **#** | **Search terms** | **Number of citations** |
| #1 | Randomized controlled trial [Publication Type] | 475831 |
| #2 | Controlled clinical trial [Publication Type] | 563869 |
| #3 | Randomized [Title/Abstract] | 557804 |
| #4 | Placebo [Title/Abstract] | 201942 |
| #5 | Drug therapy [MeSH Subheading] | 208035 |
| #6 | Randomly [Title/Abstract] | 304566 |
| #7 | Trial [Title/Abstract] | 917888 |
| #8 | Groups [Title/Abstract] | 3333446 |
| #9 | #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 | 5745480 |
| #10 | Animals [MeSH Terms] NOT Humans [MeSH Terms] | 4540890 |
| #11 | #9 NOT #10 | 4965653 |
| #12 | Fabry Disease [MeSH Terms] | 3221 |
| #13 | Fabry Disease [All Fields] | 4308 |
| #14 | Anderson-Fabry [All Fields] | 328 |
| #15 | (Anderson AND Fabry) [All Fields] | 377 |
| #16 | Angiokeratoma Corporis Diffusum [All Fields] | 4381 |
| #17 | Ceramide trihexosidase deficiency [All Fields] | 4309 |
| #18 | Ruiter pompen [All Fields] | 7 |
| #19 | Sweeley Klionsky [All Fields] | 2 |
| #20 | Alpha-galactosidase A deficiency [All Fields] | 4308 |
| #21 | Hereditary dystopic lipidosis [All Fields] | 4308 |
| #22 | GLA deficiency [All Fields] | 4722 |
| #23 | #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 | 4822 |
| #24 | agalsidase alfa [Supplementary Concept] | 112 |
| #25 | agalsidase alfa [All Fields] | 182 |
| #26 | agalsidase alpha [All Fields] | 256 |
| #27 | Replagal [All Fields]  | 187 |
| #28 | Shire AND Enzyme Replacement Therapy [All Fields] | 120 |
| #29 | #24 OR #25 OR #26 OR #27 OR #28 | 397 |
| #30 | agalsidase beta [Supplementary Concept] | 211 |
| #31 | agalsidase beta [All Fields] | 286 |
| #32 | Fabrazyme [All Fields] | 286 |
| #33 | Genzyme AND Enzyme Replacement Therapy [All Fields] | 214 |
| #34 | #30 OR #31 OR #32 OR #33 | 469 |
| #35 | #29 OR #34 | 657 |
| #36 | #11 AND #23 AND #29a | **238** |
| #37 | #11 AND #23 AND #34b | **233** |
| #38 | #11 AND #23 AND #35c | **328** |

Abbreviations: GLA, galactosidase A; MeSH, medical subject headings;

Notes: a Potential search terms to identify agalsidase alfa vs placebo trials to address research question 1

b Potential search terms to identify agalsidase beta vs placebo trials to address research question 2

c Potential search terms to identify agalsidase alpha vs agalsidase beta trials to address research question 3

≠ Date of search for reproducibility 31 Jan 2019

Potential search terms: ToR 4

ToR 4 involves a systematic review of peer-reviewed papers and grey literature. As part of the systematic review, various data sources and databases will be examined to search for relevant evidence. The following search terms will be used for the systematic review in ToR 4:

(“Fabry disease” OR “Anderson-Fabry” OR “Fabry” OR "angiokeratoma corporis diffusum" OR "Hereditary dystopic lipidosis" OR "Alpha-galactosidase A deficiency" OR "GLA deficiency" OR “GLA mutation” OR “GLA polymorphism” OR "Ceramide trihexosidase deficiency") AND ("patient centred outcome" OR "patient centered outcome" OR "patient reported outcome" OR "patient related outcome" OR “patient outcome” OR “self-reported”)

Potential search terms: ToR 5

For the search of economic evaluations:

(“Fabry” OR “Anderson-Fabry” OR "angiokeratoma corporis diffusum" OR "Hereditary dystopic lipidosis" OR "Alpha-galactosidase A deficiency" OR "GLA deficiency" OR "Ceramide trihexosidase deficiency")

AND

(Economics[Mesh:NoExp] OR "Costs and Cost Analysis"[mh] OR Economics, Nursing[mh] OR Economics, Medical[mh] OR Economics, Pharmaceutical[mh] OR Economics, Hospital[mh] OR Economics, Dental[mh] OR "Fees and Charges"[mh] OR Budgets[mh] OR budget\*[tiab] OR economic\*[tiab] OR cost[tiab] OR costs[tiab] OR costly[tiab] OR costing[tiab] OR price[tiab] OR prices[tiab] OR pricing[tiab] OR pharmacoeconomic\*[tiab] OR pharmaco-economic\*[tiab] OR expenditure[tiab] OR expenditures[tiab] OR expense[tiab] OR expenses[tiab] OR financial[tiab] OR finance[tiab] OR finances[tiab] OR financed[tiab] OR value for money[tiab] OR monetary value\*[tiab] OR models, economic[mh] OR economic model\*[tiab] OR markov chains[mh] OR markov[tiab] OR monte carlo method[mh] OR monte carlo[tiab] OR Decision Theory[mh] OR decision tree\*[tiab] OR decision analy\*[tiab] OR decision model\*[tiab])

For the search of quality of life:

(“Fabry” OR “Anderson-Fabry” OR "angiokeratoma corporis diffusum" OR "Hereditary dystopic lipidosis" OR "Alpha-galactosidase A deficiency" OR "GLA deficiency" OR "Ceramide trihexosidase deficiency")

AND

("Value of Life"[mh] OR Quality of Life[mh] OR quality of life[tiab] OR Quality-Adjusted Life Years[mh] OR quality adjusted life[tiab] OR qaly\*[tiab] OR qald\*[tiab] OR qale\*[tiab] OR qtime\*[tiab] OR life year[tiab] OR life years[tiab] OR disability adjusted life[tiab] OR daly\*[tiab] OR sf36[tiab] OR sf 36[tiab] OR short form 36[tiab] OR shortform 36[tiab] OR short form36[tiab] OR shortform36[tiab] OR sf6[tiab] OR sf 6[tiab] OR short form 6[tiab] OR sf6d[tiab] OR sf 6d[tiab] OR short form 6d[tiab] OR sf8[tiab] OR sf 8[tiab] OR short form 8[tiab] OR sf12[tiab] OR sf 12[tiab] OR short form 12[tiab] OR sf16[tiab] OR sf 16[tiab] OR sf20[tiab] OR sf 20[tiab] OR short form 20[tiab] OR hql[tiab] OR hqol[tiab] OR h qol[tiab] OR hrqol[tiab] OR hr qol[tiab] OR hye[tiab] OR hyes[tiab] OR healthy year equivalent\*[tiab] OR healthy years equivalent\*[tiab] OR pqol[tiab] OR qls[tiab] OR quality of well being[tiab] OR index of wellbeing[tiab] OR qwb[tiab] OR nottingham health profile\*[tiab] OR sickness impact profile[tiab] OR health status indicators[mh] OR health utilit\*[tiab] OR health status[tiab] OR disutilit\*[tiab] OR rosser[tiab] OR willingness to pay[tiab] OR standard gamble\*[tiab] OR time trade off[tiab] OR time tradeoff[tiab] OR tto[tiab] OR hui[tiab] OR hui1[tiab] OR hui2[tiab] OR hui3[tiab] OR eq[tiab] OR euroqol[tiab] OR euro qol[tiab] OR eq5d[tiab] OR eq 5d[tiab] OR euroqual[tiab] OR euro qual[tiab] OR duke health profile[tiab] OR functional status questionnaire[tiab] OR dartmouth coop functional health assessment\*[tiab] OR (utilit\*[tiab] AND (valu\*[tiab] OR measur\*[tiab] OR health[tiab] OR life[tiab] OR estimat\*[tiab] OR elicit\*[tiab] OR disease[tiab] OR score\*[tiab] OR weight[tiab])) OR (preference\*[tiab] AND (valu\*[tiab] OR measur\*[tiab] OR health[tiab] OR life[tiab] OR estimat\*[tiab] OR elicit\*[tiab] OR disease[tiab] OR score\*[tiab] OR instrument[tiab] OR instruments[tiab])))

Potential search terms: ToR 6

(“Fabry” OR “Anderson-Fabry” OR "angiokeratoma corporis diffusum" OR "Hereditary dystopic lipidosis" OR "Alpha-galactosidase A deficiency" OR "GLA deficiency" OR "Ceramide trihexosidase deficiency")

AND

(“Adherence, Medication” OR “Medication Nonadherence” OR “Nonadherence, Medication” OR “Medication Noncompliance” OR “Noncompliance, Medication” OR “Medication Non-Adherence” OR “Medication Non Adherence” OR “Non-Adherence, Medication” OR “Medication Persistence” OR “Persistence, Medication” OR “Medication Compliance” OR “Compliance, Medication” OR “Medication Non-Compliance” OR “Medication Non Compliance” OR “Non-Compliance, Medication”)

AND utilisation OR utilization

AND

(“agalsidase alfa” OR replagal OR “recombinant alpha-galactosidase A” OR “agalsidase beta” OR fabrazyme)

Potential search terms: ToR 7

“Fabry” OR “Anderson-Fabry” OR "angiokeratoma corporis diffusum" OR "Hereditary dystopic lipidosis" OR "Alpha-galactosidase A deficiency" OR "GLA deficiency" OR "Ceramide trihexosidase deficiency"("Fabry disease" OR Fabry) AND ((orphan AND (drug OR therap\* OR medicine OR device\*)) OR (diagnos\* OR (screen OR screening) OR (device\* OR test)) OR (future OR novel OR emerging))

: Horizon scan data sources and emerging technology assessment

For the purposes of the horizon scan, the data sources listed in

Table E-1: will be searched for emerging technologies for Fabry disease.

Table E-1: List of resources to be used in the horizon scan

|  |  |
| --- | --- |
| **Data source**  | **Website** |
| **Peer-reviewed databases** |
| Embase | http://www.ovid.com/site/catalog/databases/903.jsp |
| PubMed | https://www.ncbi.nlm.nih.gov/pubmed/ |
| Cochrane Library | https://www.cochranelibrary.com/ |
| **International organisations** |
| National Institutes of Health (NIH) | https://www.nih.gov/ |
| NIH National Centre for Advancing Translational Sciences  | https://ncats.nih.gov/index.php |
| NIH Office of Intermural Research Office of Technology Transfer  | https://www.ott.nih.gov/resources |
| NIH National Human Genome Research Institute  | https://www.genome.gov/ |
| **Early assessment & alert systems** |
| National Horizon Scanning Centre | <https://www.nihr.ac.uk/research-and-impact/emerging-health-technologies/horizon-scanning-research.htm> |
| EuroScan | <http://euroscan>.org.uk/ |
| SPS NIH | <https://www.sps.nhs.uk/?s&cat%5B0%5D=3342>  |
| **HTA / Independent research organisations** |
| Agency for Healthcare Research and Quality (AHRQ) | https://www.ahrq.gov/research/findings/evidence-based-reports/search.html |
| Canadian Agency for Drugs and Technologies in Health (CADTH):CADTH Health Technology UpdateCADTH Issues in Emerging Technology | <https://www.cadth.ca/><https://www.cadth.ca/reports?keywords=&product_type%5B%5D=107327&sort=field_date%3Avalue-desc&amount_per_page=10&email_address=&page=1>[https://www.cadth.ca/reports?keywords=&result\_type[]=report&product\_type[]=107322&sort=field\_date%3Avalue-desc&amount\_per\_page=10&email=&page=1](https://www.cadth.ca/reports?keywords=&result_type%5b%5d=report&product_type%5b%5d=107322&sort=field_date%3Avalue-desc&amount_per_page=10&email=&page=1) |
| Haute Autorité de Santé (HAS) | https://www.has-sante.fr/portail/jcms/r\_1455081/Home-page |
| National Institute for Health & Clinical Excellence (NICE) | http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information |
| National Coordinating Centre for Health Technology Assessment | http://www.ncchta.org |
| Scottish Medicines Consortium (SMC) | https://www.scottishmedicines.org.uk/about-us/horizon-scanning/ |
| **Regulatory agencies** |
| Therapeutic Goods Administration (TGA) | http://www.tga.gov.au/ |
| US Food and Drug Administration (FDA)FDA Office of Orphan Drugs Development | http://www.fda.gov/default.htmhttps://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/officeofscienceandhealthcoordination/ucm2018190.htm |
| European Medicines Agency (EMA) | http://www.ema.europa.eu/en/ |
| **News** |  |
| PharmaTimes | http://www.pharmatimes.com/ |
| Healio | http://www.healio.com/ |
| EurekAlert!  | http://www.eurekalert.org/ |
| Medpage Today | <http://www>.medpagetoday.com/ |
| PharmaLive | https://www.pharmalive.com/ |
| PR Newswire | <https://www.prnewswire.com/> |
| **Clinical trials registries** |
| Australian New Zealand Clinical Trials Registry (ANZCTR) | <http://www>.anzctr.org.au/ |
| EU Clinical Trials Register | https://www.clinicaltrialsregister.eu/ |
| National Institute of Health - U.S. National Library of Medicine | https://clinicaltrials.gov/ct2/home |
| Current Controlled Trials metaRegister (US and UK clinical trial registers) | http://www.isrctn.com/ |
| **Other** |
| Orphanet | <https://www.orpha.net/consor/cgi-bin/index.php>  |
| Rare Voices  | https://www.rarevoices.org.au/ |
| NORD | https://rarediseases.org/ |
| Eurordis | https://www.eurordis.org |
| F1000Poster | https://f1000research.com/ |

Abbreviations: AHRQ, Agency for Healthcare Research and Quality; ASHP, American Society of Health-System Pharmacists; CADTH, Canadian Agency for Drugs and Technologies in Health; EMA, European medicines agency; EU, European union; FDA, Food and drug administration; HAS, Haute Autorité de Santé; HTA Health technology assessment; KCE, Belgian Health Care Knowledge Centre; NCCHTA, National Coordinating Centre for Health Technology Assessment; NECA, National Evidence-based healthcare Collaborating Agency; NHS CRD, University of York NHS Centre for Reviews and Dissemination; NHS HTA, National Health Service Health Technology Assessment (UK); NHMRC, National Health and Medical Research Council; NICE, National Institute for Health and Care Excellence; SPS NHS, Specialist Pharmacist Service NHS; SMC, Scottish Medicines Consortium; TGA, Therapeutic goods administration

The developing technology summary sheet in Table E-2 is to be completed for upcoming treatments and tests that could impact future access for Fabry disease patients. The goal of the summary sheet is to provide a synopsis of the identified technology, in addition to its clinical and regulatory progress to date. Furthermore, the table will also provide information regarding other pieces of information that address one or more of the multiple dot points under Section 8.9. Sources for all pieces of information use in the developing technology summary sheet will also be provided for easy referencing.

Table E-2: Developing technology summary sheet

|  |
| --- |
| **Developing technology summary sheet** |
| **Product brief** |
| Proprietary name: |
| Type of technology (test/treatment [functional agent name]): |
| Method of action: |
| Stage of development (Pre-clinical – Phase IV): |
| Indicated for Fabry disease?* If yes, what is the official indication?
 |
| Approved for Fabry disease in Australia?* Provide the ARTG number (if available):
 |
| Registered elsewhere (if yes, list all countries)? |
| **Clinical trials** |
| Study title*Trial number* | Trial status | Intervention/treatment | Site Locations (n) | Trial outcomes (primary and secondary) |
|  |  |  |  |  |
| **Other** |
|  |
| **Sources** |
|  |

1. A genetic alteration that increases an individual's susceptibility or predisposition to a certain disease or disorder. When such a variant (or mutation) is inherited, development of symptoms is more likely, but not certain. [↑](#footnote-ref-2)